Page last updated: 2024-10-23

aspirin and Sinusitis

aspirin has been researched along with Sinusitis in 264 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Sinusitis: Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES.

Research Excerpts

ExcerptRelevanceReference
"Aspirin-induced chronic rhinosinusitis (CRS) is a severe progressive persistent disease, usually associated with nasal polyps (NPs)."9.30Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery. ( Barać, A; Gaćeša, D; Jožin, SM; Kovačević, SV; Perić, A; Perić, AV, 2019)
"Numerous open trials have demonstrated the beneficial clinical effects of aspirin desensitization (AD) in patients with aspirin-induced asthma (AIA)."9.19Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. ( Bochenek, G; Ćmiel, A; Gielicz, A; Niżankowska-Mogilnicka, E; Plutecka, H; Sanak, M; Stręk, P; Świerczyńska-Krępa, M; Szczeklik, A, 2014)
"Aspirin-exacerbated respiratory disease (AERD) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance to medications that inhibit the cycloxgenase-1 enzyme."9.12The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, ( Baptist, AP; Borish, L; Bosso, JV; Buchheit, KM; Cahill, KN; Campo, P; Cho, SH; Jerschow, E; Keswani, A; Laidlaw, TM; Levy, JM; Nanda, A; Stevens, WW; White, AA, 2021)
"Patients with asthma who have aspirin sensitivity have greater cysteinyl leukotriene production and greater airway hyperresponsiveness to the effects of inhaled cysteinyl leukotrienes than their aspirin-tolerant counterparts."9.10Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. ( Corrigan, CJ; Lee, TH; Parikh, A; Scadding, G; Sousa, AR, 2002)
"Aspirin-Exacerbated Respiratory Disease (AERD) and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) are both characterized by the presence of chronic sinonasal inflammation and nasal polyps."8.93Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis. ( Schleimer, RP; Stevens, WW, 2016)
"Aspirin-exacerbated respiratory disease (AERD) is a clinical condition which results in adverse upper and lower respiratory symptoms, particularly rhinitis, conjunctivitis, bronchospasm, and/or laryngospasm, following exposure to cyclooxygenase-1 (COX-1) inhibiting drugs, namely aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)."8.91Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). ( Dazy, KM; Simon, RA; Waldram, JD, 2015)
"Chronic rhinosinusitis patients with nasal polyps can be aspirin sensitive or aspirin tolerant."8.90Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis. ( Parikh, A; Scadding, GK, 2014)
"Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma frequently coexist and are always present in patients with aspirin exacerbated respiratory disease (AERD)."8.90Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity. ( Machado-Carvalho, L; Picado, C; Roca-Ferrer, J, 2014)
"The presence of aspirin-exacerbated respiratory disease (AERD) in a patient with chronic rhinosinusitis with nasal polyps and asthma is associated with severe eosinophilic upper and lower airway disease."8.89Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. ( Mullol, J; Picado, C, 2013)
"This review is set to revisit the pathogenesis of aspirin-exacerbated respiratory disease (AERD), the diagnostic method used, and finally the real impact of aspirin desensitization on chronic sinusitis with nasal polyposis (CRSwNP) in aspirin intolerant patients."8.87Role of aspirin desensitization in the management of chronic rhinosinusitis. ( Rizk, H, 2011)
"NSAIDs-including aspirin (ASA)-that inhibit cyclooxygenase (COX)-1 induce nonallergic hypersensitivity reactions consisting of attacks of rhinitis and asthma."8.85Aspirin sensitivity and desensitization for asthma and sinusitis. ( Stevenson, DD, 2009)
"The purpose of this review is to highlight recent advances in gene-expression profiling of nasal polyps in patients with chronic rhinosinusitis and aspirin-sensitive asthma."8.85Gene-expression signatures of nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma. ( Metson, R; Platt, M; Stankovic, K, 2009)
"Aspirin-exacerbated respiratory disease (AERD) is a chronic inflammatory disease characterized by chronic rhinosinusitis, nasal polyposis, asthma, and airway reactivity to aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs)."8.84The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis. ( Williams, AN; Woessner, KM, 2008)
"Interesting findings relating to aspirin-induced asthma recently emerged."8.81Aspirin-induced rhinitis and asthma. ( Nizankowska, E; Sanak, M; Swierczynska, M; Szczeklik, A, 2001)
"Aspirin-sensitive rhinosinusitis is a non-allergic, non-infectious perennial eosinophilic rhinitis starting in middle age and rarely seen in children."8.79Phenomenology, pathogenesis, diagnosis and treatment of aspirin-sensitive rhinosinusitis. ( Schapowal, AG; Schmitz-Schumann, M; Simon, HU, 1995)
"Patients with asthma and nasal polyps have been warned to avoid aspirin because of a tendency to develop hypersensitivity reactions."8.77Desensitization to aspirin in aspirin-sensitive patients with rhino-sinusitis and asthma: a review. ( Knight, A, 1989)
"Aspirin-exacerbated respiratory disease (AERD) is a phenotype of severe asthma, but its disease course has not been well documented compared with that of aspirin-tolerant asthma (ATA)."8.31Long-term clinical outcomes of aspirin-exacerbated respiratory disease: Real-world data from an adult asthma cohort. ( Kim, C; Lee, E; Lee, HY; Lee, Y; Park, HS; Park, RW; Woo, SD; You, SC, 2023)
" The coexistence of CRS, bronchial asthma and aspirin intolerance (aspirin triad) is an adverse prognostic factor with higher risk of recurrences."7.91Analysis of the impact of bronchial asthma and hypersensitivity to aspirin on the clinical course of chronic sinusitis with nasal polyps. ( Dąbrowska, K; Fendler, W; Pagacz, K; Pietruszewska, W; Podwysocka, M, 2019)
" Aspirin-exacerbated respiratory disease (AERD) is defined as asthma, chronic rhinosinusitis with nasal polyposis, and hypersensitivity to cyclooxygenase-1 inhibitors."7.85Immunoglobulin G4 sinusitis in association with aspirin-exacerbated respiratory disease. ( Johal, K; Peters, A; Welch, K, 2017)
"Aspirin hypersensitivity associated with chronic rhinosinusitis-with or without nasal polyposis-and asthma resistant to conventional therapy defines the aspirin-exacerbated respiratory disease (AERD)."7.85Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria. ( Cutrera, R; Di Marco, A; Porcaro, F, 2017)
" In our previous studies, we showed that the TNFA -308A allele is a genetic predisposition factor in a subgroup of aspirin-sensitive (ASA+) CRS patients suffering from nasal polyps (NP) in the Hungarian population."7.81A conserved linkage group on chromosome 6, the 8.1 ancestral haplotype, is a predisposing factor of chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarians. ( Bella, Z; Hirschberg, A; Kadocsa, E; Kemény, L; Kiricsi, Á; Polyánka, H; Révész, M; Szabó, K; Szabó, Z; Széll, M; Vóna, I, 2015)
"Chronic rhinosinusitis (CRS) with nasal polyposis (NP) may be associated with hypersensitivity to nonsteroidal anti-inflammatory drugs, representing a syndrome of aspirin-exacerbated respiratory disease (AERD)."7.78Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4. ( Celejewska-Wójcik, N; Cybulska, A; Hartwich, P; Hydzik-Sobocińska, K; Januszek, R; Mastalerz, L; Nieckarz, R; Oleś, K; Sanak, M; Stręk, P; Szaleniec, J; Wójcik, K, 2012)
"The present study inluded 22 patients presenting either with very severe or moderately severe aspirin triad 17 of whom suffered exacerbation of chronic polypous suppurative rhinosinusitis."7.77[The treatment of polypous suppurative rhinosinusitis in the patients presenting with the severe and moderate aspirin triad]. ( Riabova, MA; Shumilova, NA, 2011)
"Among the patients with asthma, polymorphism at -1082A/G was significantly associated with the phenotype of aspirin-intolerant asthma, AIA (P = 0."7.75Combined effect of IL-10 and TGF-beta1 promoter polymorphisms as a risk factor for aspirin-intolerant asthma and rhinosinusitis. ( Cho, BY; Kim, SH; Lee, HN; Park, HS; Yang, EM; Ye, YM, 2009)
"Without prior exposure to aspirin or NSAIDs, the chance of a positive OAC was 5 in 12 (42%) but was 198 in 231 (86%) for those with a history of aspirin- and NSAID-associated asthma attacks."7.74Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. ( Dursun, AB; Karasoy, D; Simon, RA; Stevenson, DD; Woessner, KA, 2008)
"Rhinosinusitis is highly associated with aspirin-intolerant asthma (AIA)."7.74Association between a TGFbeta1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients. ( Holloway, JW; Kim, SH; Park, CS; Park, HS; Shin, HD, 2007)
"To identify genes whose expression is most characteristic of chronic rhinosinusitis and aspirin-sensitive asthma through genome-wide transcriptional profiling of nasal polyp tissue."7.74Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma. ( Goldsztein, H; Metson, R; Platt, MP; Reh, DD; Stankovic, KM, 2008)
"Cysteinyl leukotrienes play a disease-regulating role in rhinosinusitis and asthma, particularly aspirin-sensitive disease."7.73Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. ( Corrigan, C; Lee, T; Mallett, K; Parikh, A; Roberts, D; Scadding, G; Ying, S, 2005)
"Data were compared between asthmatic patients who reported exacerbations after aspirin ingestion and those who did not."7.73Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. ( Borish, L; Hunt, J; Mascia, K; Patrie, J; Phillips, CD; Steinke, JW, 2005)
"To address the hypothesis that expression of 1 or more EP receptors on nasal mucosal inflammatory cells is deficient in patients with aspirin-sensitive compared with nonaspirin-sensitive polypoid rhinosinusitis."7.73Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. ( Corrigan, CJ; Lee, TH; Meng, Q; Parikh, A; Scadding, G; Ying, S, 2006)
"The urinary leukotriene E4 (U-LTE4) concentration is significantly increased in patients with aspirin-intolerant asthma (AIA)."7.72Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. ( Akiyama, K; Higashi, A; Higashi, N; Ishii, T; Kawagishi, Y; Mita, H; Osame, M; Taniguchi, M, 2004)
"Although many studies have assumed that the overproduction of cysteinyl- leukotrienes (cys-LTs) and an imbalance of arachidonic acid metabolism may be plausible causes for the pathogenesis of aspirin-intolerant asthma (AIA), there has been little experimental evidence to substantiate this notion in lower airways of patients with AIA."7.71A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. ( Akiyama, K; Higashi, N; Mita, H; Osame, M; Taniguchi, M, 2002)
"Patients with aspirin-hypersensitive rhinosinusitis/asthma suffer from a severe form of hyperplastic rhinosinusitis with recurrent polyposis."7.71Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity. ( Danilewicz, M; Grzegorczyk, J; Kornatowski, T; Kowalski, ML; Pawliczak, R; Wagrowska-Danilewicz, M, 2002)
"The aspirin triad (nasal polyposis, asthma and sensitivity to aspirin) is a well-recognized clinical entity, also known as aspirin-induced asthma (AIA)."7.70Effects of sinus surgery on asthma in aspirin triad patients. ( Higuchi, Y; Kawasaki, M; Nakamura, H; Takahashi, S, 1999)
"This study confirms the importance of eosinophil infiltration in the pathogenesis of severe or recurrent nasal polyps based on allergy and aspirin intolerance."7.70[Significance of eosinophilic granulocytes in relation to allergy and aspirin intolerance in patients with sinusitis polyposa]. ( Bittinger, F; Gosepath, J; Kaldenbach, T; Klimek, L; Mann, WJ; Schäfer, D, 1999)
"The high prevalence of aspirin intolerance in asthmatics and patients with nasal polyps as well as reports of familial clustering suggest a genetic disposition of this disease."7.70[Family study of patients with aspirin intolerance and rhinosinusitis]. ( Langenbeck, U; May, A; Wagner, D; Weber, A, 2000)
" In contrast, the sinusitis of the aspirin triad syndrome is often fulminate, expansive, and recurrent, and complications may be more frequent."7.69Orbital complications of sinusitis in the aspirin triad syndrome. ( Massaro, BM; McFadden, EA; Toohill, RJ; Woodson, BT, 1996)
"Aspirin-sensitive patients with asthma experience continuous inflammation of their nasal and sinus tissues, complicated by recurrent sinusitis, which frequently leads to asthma attacks."7.69Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. ( Christiansen, SC; Hankammer, MA; Mathison, DA; Simon, RA; Stevenson, DD, 1996)
"We attempted to determine the relationship of nasal polyps to histamine (HA) metabolism."7.68Histamine metabolism in nasal polyps. ( Abe, Y; Fukui, H; Harada, T; Imamura, I; Irifune, M; Matsunaga, T; Ogino, S, 1993)
"An 11-year retrospective study was conducted to evaluate the surgical treatment of sinusitis in aspirin-triad patients."7.68Surgery for sinusitis and aspirin triad. ( Fink, JN; Kany, RJ; McFadden, EA; Toohill, RJ, 1990)
"One hundred seven known aspirin (ASA)-sensitive patients with rhinosinusitis-asthma were studied from 1975 to 1988."7.68Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma. ( Mathison, DA; Simon, RA; Stevenson, DD; Sweet, JM, 1990)
"Nearly 700 specimens of polyps and sinus tissues from 12 patients with asthma and aspirin idiosyncrasy were studied with histochemical and immunofluorescent immunoglobulin techniques."7.67Histopathology and immunofluorescent immunoglobulins in asthmatics with aspirin idiosyncrasy. ( Carr, R; English, GM; Farr, R; Spector, S, 1987)
"Seventy-four asthmatic patients seen in a hospital were challenged with aspirin."7.67Prevalence of aspirin intolerance in asthmatics treated in a hospital. ( Castillo, JA; Picado, C, 1986)
"This study attempted to determine whether or not nasal and sinus surgery had a beneficial or deleterious effect upon the asthma of patients with nasal polyps and aspirin idiosyncrasy."7.67Nasal polypectomy and sinus surgery in patients with asthma and aspirin idiosyncrasy. ( English, GM, 1986)
"In order to determine the types of respiratory responses observed during aspirin-induced reactions, 50 consecutive asthmatic patients with a history of aspirin sensitivity underwent prospective oral aspirin challenges between 1979 and 1981."7.66Aspirin-sensitive rhinosinusitis/asthma: spectrum of adverse reactions to aspirin. ( Mathison, DA; Pleskow, WW; Schatz, M; Simon, RA; Stevenson, DD; Zeiger, RS, 1983)
"Aspirin-sensitive asthma is not well documented in children."7.66Aspirin-induced asthma in children. ( Collins-Williams, C; Tan, Y, 1982)
"Chronic rhinosinusitis with nasal polyposis may be a symptom of aspirin-intolerance."7.65[Rhinosinusitis polyposa as the only symptom of aspirin intolerance -- a rhinorheomanometric diagnosis (author's transl)]. ( Enzmann, H; Kühn, H, 1977)
" We conducted network meta-analysis of sinusitis symptoms, heath-related quality of life, rescue oral corticosteroids and surgery, endoscopic and radiologic scores, and adverse events."6.82Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. ( Bousquet, J; Brignardello-Petersen, R; Chu, DK; Kennedy, DW; Oykhman, P; Paramo, FA, 2022)
"Sinusitis is very common, so it is important to understand its pathophysiology, diagnosis, and medical and surgical treatments."6.43Sinusitis: allergies, antibiotics, aspirin, asthma. ( Radojicic, C, 2006)
"Aspirin sensitivity has a highly significant association with AFRS."5.48Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. ( Ahmed, S; Almeyda, R; Anari, S; Carrie, S; Cathcart, R; Clark, A; Coombes, E; Erskine, S; Farboud, A; Hobson, J; Hopkins, C; Jervis, P; Kara, N; Khalil, H; Kumar, N; Mansell, N; Panesaar, J; Philpott, C; Philpott, CM; Prinsley, P; Ray, J; Robertson, A; Salam, M; Sunkaraneni, S; Sunkaraneni, V; Wilson, A; Woods, J, 2018)
"Aspirin-exacerbated respiratory disease (AERD) is characterized by abnormal arachidonic acid metabolism leading to chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, and upper and/or lower respiratory symptoms after ingestion of cyclooxygenase-1 inhibiting nonsteroidal antiinflammatory drugs."5.41Aspirin-Exacerbated Respiratory Disease and the Unified Airway: A Contemporary Review. ( Choby, G; Divekar, RD; Hagan, JB; O'Brien, EK; Pinheiro-Neto, CD; Stokken, JK; Walters, BK; Willson, TJ, 2023)
"Aspirin-exacerbated respiratory disease (AERD) is a chronic respiratory condition characterized by severe chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic asthma, and respiratory reactions to cyclooxygenase inhibitors."5.41Aspirin-exacerbated respiratory disease: Updates in the era of biologics. ( Buchheit, KM; Mullur, J, 2023)
"Aspirin-exacerbated respiratory disease (AERD) is characterized by eosinophilic rhinosinusitis, nasal polyposis, and bronchial asthma, along with the onset of respiratory reactions after the ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs) or acetylsalicylic acid (ASA)."5.41Effect of low salicylate diet on clinical and inflammatory markers in patients with aspirin exacerbated respiratory disease - a randomized crossover trial. ( Patel, KB; Rocha, T; Rotenberg, BW; Schmerk, C; Sommer, DD; Sowerby, LJ, 2021)
"These post hoc analyses of pooled data from 2 BREATH phase 3 clinical trials, studies 1 and 2 (NCT01287039 and NCT01285323), examined asthma-related outcomes in patients with comorbid, self-reported CRSwNP with and without aspirin sensitivity."5.30Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. ( Bardin, P; Bateman, ED; Garin, M; Germinaro, M; Hoyte, FCL; Katial, RK; Korn, S; McDonald, M; Weinstein, SF, 2019)
"Aspirin-induced chronic rhinosinusitis (CRS) is a severe progressive persistent disease, usually associated with nasal polyps (NPs)."5.30Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery. ( Barać, A; Gaćeša, D; Jožin, SM; Kovačević, SV; Perić, A; Perić, AV, 2019)
"of our patients with bronchial asthma."5.27[Inhalation provocation test with lysine acetylsalicylic acid (Aspisol)--a useful method for the diagnosis of analgesic asthma]. ( Kirsten, D; Meister, W; Treutler, D, 1984)
"Aspirin exacerbated respiratory disease (AERD) is comprised of aspirin/acetylsalicylic acid (ASA) sensitivity, bronchial asthma, and nasal polyposis."5.20Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study. ( Au, M; Gupta, MK; Hoffbauer, S; Nayan, S; Sommer, DD; Sowerby, LJ, 2015)
"Numerous open trials have demonstrated the beneficial clinical effects of aspirin desensitization (AD) in patients with aspirin-induced asthma (AIA)."5.19Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. ( Bochenek, G; Ćmiel, A; Gielicz, A; Niżankowska-Mogilnicka, E; Plutecka, H; Sanak, M; Stręk, P; Świerczyńska-Krępa, M; Szczeklik, A, 2014)
"To determine acute analgesia by acetylsalicylic acid (ASA) when combined with pseudoephedrine (PSE) in patients with upper respiratory tract infection (URTI), we used the sore throat pain model to measure single-dose effects of ASA 500 mg/PSE 30 mg, ASA 1000 mg/PSE 60 mg, and acetaminophen (APAP) 1000 mg/PSE 60 mg (serving as a positive control)."5.14Demonstration of the analgesic efficacy and dose-response of acetylsalicylic acid with pseudoephedrine. ( Becka, M; Bey, M; Gagney, D; Sanner, KM; Schachtel, BP; Schachtel, EJ; Voelker, M, 2010)
"Twenty-one adult patients with asthma, chronic polypoid sinusitis, and a convincing history of acute respiratory reaction to the ingestion of aspirin or nonsteroidal anti-inflammatory drugs were selected."5.14The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. ( Alam, R; Katial, RK; Leung, R; Prasertsuntarasai, T; Strand, M; Zheng, W, 2010)
"Aspirin-exacerbated respiratory disease (AERD) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance to medications that inhibit the cycloxgenase-1 enzyme."5.12The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, ( Baptist, AP; Borish, L; Bosso, JV; Buchheit, KM; Cahill, KN; Campo, P; Cho, SH; Jerschow, E; Keswani, A; Laidlaw, TM; Levy, JM; Nanda, A; Stevens, WW; White, AA, 2021)
"Aspirin-exacerbated respiratory disease (AERD) is a condition composed of chronic rhinosinusitis with nasal polyposis and asthma that is defined by respiratory hypersensitivity reactions to the cyclooxygenase 1-inhibitory effects of nonsteroidal anti-inflammatory drugs."5.12Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease. ( Haque, R; Hopkins, C; Jackson, DJ; White, AA, 2021)
"Patients with asthma who have aspirin sensitivity have greater cysteinyl leukotriene production and greater airway hyperresponsiveness to the effects of inhaled cysteinyl leukotrienes than their aspirin-tolerant counterparts."5.10Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. ( Corrigan, CJ; Lee, TH; Parikh, A; Scadding, G; Sousa, AR, 2002)
"Aspirin-exacerbated respiratory disease (AERD) represents an aggressive form of chronic rhinosinusitis with nasal polyposis that is notoriously challenging to treat."5.05Aspirin desensitization therapy in aspirin-exacerbated respiratory disease: a systematic review. ( Chin, CJ; Larivée, N, 2020)
"NSAID-Exacerbated respiratory disease (also known as Samter's or Widal's triad, aspirin-exacerbated respiratory disease) is characte- rized by asthma, nasal polyposis and hypersensitivity to NSAIDs."5.05[Widal's triad : clinical manifestations, pathophysiology and therapeutic advances]. ( Jandus, P; Landis, BN; Vandenberghe-Dürr, S, 2020)
"Aspirin-exacerbated respiratory disease is a chronic and treatment-resistant disease, characterized by the presence of eosinophilic rhinosinusitis, nasal polyposis, bronchial asthma, and nonsteroidal anti-inflammatory drugs hypersensitivity."4.98Aspirin exacerbated respiratory disease: Current topics and trends. ( Guaní-Guerra, E; Moreno-Paz, FJ; Rodríguez-Jiménez, JC; Terán, LM, 2018)
"Aspirin-exacerbated respiratory disease (AERD) refers to the combination of asthma, chronic rhinosinusitis with nasal polyposis, and acute upper and lower respiratory tract reactions to the ingestion of aspirin (acetylsalicylic acid, ASA) and other cyclooxygenase-1 inhibiting non-steroidal anti-inflammatory drugs."4.95Aspirin-exacerbated respiratory disease and current treatment modalities. ( Cingi, C; Kar, M; Muluk, NB; Sakalar, EG, 2017)
"Aspirin-exacerbated respiratory disease (AERD) represents a severe form of chronic rhinosinusitis (CRS) characterized by nasal polyposis, bronchial asthma, and aspirin intolerance."4.93The Role of Surgery in Management of Samter's Triad: A Systematic Review. ( Adelman, J; Krouse, JH; McLean, C; Shaigany, K, 2016)
"Aspirin-Exacerbated Respiratory Disease (AERD) and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) are both characterized by the presence of chronic sinonasal inflammation and nasal polyps."4.93Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis. ( Schleimer, RP; Stevens, WW, 2016)
"Aspirin-exacerbated respiratory disease is defined by the clinical tetrad of aspirin sensitivity, nasal polyps, asthma, and chronic rhinosinusitis."4.93Current complications and treatment of aspirin-exacerbated respiratory disease. ( Cook, KA; Stevenson, DD, 2016)
"Aspirin-exacerbated respiratory disease (AERD) is a clinical condition which results in adverse upper and lower respiratory symptoms, particularly rhinitis, conjunctivitis, bronchospasm, and/or laryngospasm, following exposure to cyclooxygenase-1 (COX-1) inhibiting drugs, namely aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)."4.91Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). ( Dazy, KM; Simon, RA; Waldram, JD, 2015)
"Aspirin-exacerbated respiratory disease is a clinical entity comprising chronic rhinosinusitis with nasal polyposis, asthma and intolerance to COX-1 inhibiting drugs."4.91Aspirin-exacerbated respiratory disease: characteristics and management strategies. ( Dazy, KM; Simon, RA; Waldram, JD, 2015)
"Hypersensitivity to acetylsalicylic acid (ASA) is characterized by the co-occurrence of symptoms so-called aspirin triad, which include bronchial asthma, chronic rhinitis and sinusitis and the nasal mucosa polyps."4.91[Hypersensitivity to acetylsalicylic acid]. ( Skrętkowicz, J; Wojtczak, A, 2015)
" Several clinical phenotypes often leading to uncontrolled disease, including adult nasal polyposis, aspirin-exacerbated respiratory disease, and allergic fungal rhinosinusitis, are characterized by a common endotype: a TH2 bias is associated with a higher likelihood of comorbid asthma and recurrence after surgical treatment."4.91Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. ( Bachert, C; Gevaert, P; Zhang, L, 2015)
"Asthma has many triggers including rhinosinusitis; allergy; irritants; medications (aspirin in aspirin-exacerbated respiratory disease); and obesity."4.90Identifying asthma triggers. ( Ferguson, BJ; McCarty, JC, 2014)
"Chronic rhinosinusitis patients with nasal polyps can be aspirin sensitive or aspirin tolerant."4.90Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis. ( Parikh, A; Scadding, GK, 2014)
"Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma frequently coexist and are always present in patients with aspirin exacerbated respiratory disease (AERD)."4.90Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity. ( Machado-Carvalho, L; Picado, C; Roca-Ferrer, J, 2014)
"The presence of aspirin-exacerbated respiratory disease (AERD) in a patient with chronic rhinosinusitis with nasal polyps and asthma is associated with severe eosinophilic upper and lower airway disease."4.89Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. ( Mullol, J; Picado, C, 2013)
"This review is set to revisit the pathogenesis of aspirin-exacerbated respiratory disease (AERD), the diagnostic method used, and finally the real impact of aspirin desensitization on chronic sinusitis with nasal polyposis (CRSwNP) in aspirin intolerant patients."4.87Role of aspirin desensitization in the management of chronic rhinosinusitis. ( Rizk, H, 2011)
"NSAIDs-including aspirin (ASA)-that inhibit cyclooxygenase (COX)-1 induce nonallergic hypersensitivity reactions consisting of attacks of rhinitis and asthma."4.85Aspirin sensitivity and desensitization for asthma and sinusitis. ( Stevenson, DD, 2009)
"The purpose of this review is to highlight recent advances in gene-expression profiling of nasal polyps in patients with chronic rhinosinusitis and aspirin-sensitive asthma."4.85Gene-expression signatures of nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma. ( Metson, R; Platt, M; Stankovic, K, 2009)
"Aspirin-exacerbated respiratory disease (AERD) is a chronic inflammatory disease characterized by chronic rhinosinusitis, nasal polyposis, asthma, and airway reactivity to aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs)."4.84The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis. ( Williams, AN; Woessner, KM, 2008)
"In up to 10% of patients with bronchial asthma, aspirin and other nonsteroidal antiinflammatory drugs precipitate asthmatic attacks."4.82Aspirin intolerance and the cyclooxygenase-leukotriene pathways. ( Kiełbasa, B; Nizankowska-Mogilnicka, E; Sanak, M; Szczeklik, A, 2004)
"Recent findings supporting mechanisms that promote eosinophilic infiltration are discussed and include the following subcategories: super antigen-induced eosinophilic chronic rhinosinusitis, allergic fungal sinusitis, nonallergic fungal eosinophilic chronic rhinosinusitis, and aspirin-exacerbated eosinophilic chronic rhinosinusitis."4.82Categorization of eosinophilic chronic rhinosinusitis. ( Ferguson, BJ, 2004)
" However, recently there has been some progress in elucidating the etiology of nasal polyposis, especially regarding tissue eosinophilia as well as the role of aspirin intolerance and eicosanoid mediators."4.82Current concepts in therapy of chronic rhinosinusitis and nasal polyposis. ( Gosepath, J; Mann, WJ, 2005)
"Interesting findings relating to aspirin-induced asthma recently emerged."4.81Aspirin-induced rhinitis and asthma. ( Nizankowska, E; Sanak, M; Swierczynska, M; Szczeklik, A, 2001)
"Aspirin-sensitive rhinosinusitis is a non-allergic, non-infectious perennial eosinophilic rhinitis starting in middle age and rarely seen in children."4.79Phenomenology, pathogenesis, diagnosis and treatment of aspirin-sensitive rhinosinusitis. ( Schapowal, AG; Schmitz-Schumann, M; Simon, HU, 1995)
"Patients with asthma and nasal polyps have been warned to avoid aspirin because of a tendency to develop hypersensitivity reactions."4.77Desensitization to aspirin in aspirin-sensitive patients with rhino-sinusitis and asthma: a review. ( Knight, A, 1989)
"These evidence-based guidelines support patients, clinicians, and other stakeholders in decisions about the use of intranasal corticosteroids (INCS), biologics, and aspirin therapy after desensitization (ATAD) for the management of chronic rhinosinusitis with nasal polyposis (CRSwNP)."4.31The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. ( Bernstein, JA; Bognanni, A; Chu, DK; Ellis, AK; Golden, DBK; Greenhawt, M; Horner, CC; Ledford, DK; Lieberman, J; Luong, AU; Orlandi, RR; Oykhman, P; Peters, AT; Rank, MA; Samant, SA; Shaker, MS; Soler, ZM; Stevens, WW; Stukus, DR; Wang, J, 2023)
"A total of 30 patients with AERD, 30 chronic rhinosinusitis (CRS) with NP patients without aspirin sensitivity (CRSwNP), and 30 control subjects without inflammation of the nasal mucosa (C), selected for surgical treatment entered the study."4.31Inflammatory mediators in nasal secretions of patients with nasal polyposis with and without aspirin sensitivity. ( Cvetković, G; Gaćeša, D; Perić, A; Vojvodić, D, 2023)
" Quantitative and descriptive analyses of age, gender, nationality, presence of polyps, aspirin sensitivity, presence of urticaria, asthma, and allergies were performed."4.31Demographic and clinical profile of patients with chronic rhinosinusitis in Saudi Arabia. ( Alanazy, F; Alfallaj, R; Almousa, H; Aloulah, M; Alrasheed, A; Alromaih, S; Alroqi, AS; Alsaleh, S; Dousary, SA; Ismail, D; Mahjoub, S; Obaid, SB, 2023)
"Aspirin-exacerbated respiratory disease (AERD) is a phenotype of severe asthma, but its disease course has not been well documented compared with that of aspirin-tolerant asthma (ATA)."4.31Long-term clinical outcomes of aspirin-exacerbated respiratory disease: Real-world data from an adult asthma cohort. ( Kim, C; Lee, E; Lee, HY; Lee, Y; Park, HS; Park, RW; Woo, SD; You, SC, 2023)
"Aspirin-exacerbated respiratory disease (AERD) consists of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and hypersensitivity to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)."4.31Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data. ( Adame, MJ; Kuo, YF; Raji, M; Shan, Y; Tripple, JW; Zhang, Y, 2023)
"The impact of anosmia on quality-of-life (QoL) for patients with aspirin-exacerbated respiratory disease (AERD) is poorly understood."4.12Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life. ( Bensko, JC; Buchheit, KM; Gakpo, D; Laidlaw, TM; Lundberg, M; Maurer, R; Mullur, J; Tchekmedyian, R, 2022)
"Non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NERD) is characterized by the triad of chronic rhinosinusitis with nasal polyp, asthma, and aspirin (ASA) or NSAID hypersensitivity."4.12Clinical characteristics and aspirin desensitization in Thai patients with a suggestive history of NSAID-exacerbated respiratory disease. ( Sompornrattanaphan, M; Tantilipikorn, P; Thongngarm, T; Wongsa, C, 2022)
"Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) asthma is characterized by chronic rhinosinusitis and intolerance of aspirin and other COX1 inhibitors."4.02Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease. ( Bochenek, G; Gielicz, A; Jakiela, B; Plutecka, H; Przybyszowski, M; Rebane, A; Sladek, K; Soja, J, 2021)
"Aspirin-exacerbated respiratory disease (AERD) is a syndrome characterised by chronic rhinosinusitis, nasal polyps, asthma and aspirin intolerance."4.02Transcriptome Analysis Identifies Doublesex and Mab-3 Related Transcription Factor (DMRT3) in Nasal Polyp Epithelial Cells of Patients Suffering from Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease (AERD). ( de Graaf, J; Gratziou, C; Jiménez-Chobillon, MA; Porras Gutiérrez de Velasco, R; Priyadharshini, VS; Ramírez-Jiménez, F; Teran, LM, 2021)
"Aspirin-exacerbated respiratory disease (AERD) is a severe form of chronic rhinosinusitis with nasal polyps (CRSwNP) accompanied by asthma and an aspirin intolerance."3.96The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data. ( Eder, K; Gellrich, D; Gröger, M; Högerle, C; Pfrogner, E; San Nicoló, M, 2020)
"Aspirin-exacerbated respiratory disease (AERD) refers to the combination of asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and acute respiratory tract reactions to ingestion of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs)."3.96Aspirin-exacerbated respiratory disease: longitudinal assessment of a large cohort and implications of diagnostic delay. ( Chou, DW; Kshirsagar, RS; Liang, J; Wei, J, 2020)
"Aspirin-exacerbated respiratory disease (AERD) represents a severe endotype of chronic rhinosinusitis with nasal polyposis."3.96Surgical outcomes in aspirin-exacerbated respiratory disease without aspirin desensitization. ( Cottrell, J; Grose, E; Lee, DJ; Lee, JK; Lee, JM; Sykes, J; Yip, J, 2020)
" CRSwNP may be associated with comorbidity, mainly concerning asthma, aspirin intolerance, and allergy."3.96Clinical-Cytological-Grading and phenotyping in patients with chronic rhinosinusitis with nasal polyps: the relevance in clinical practice. ( Cassano, M; Ciprandi, G; Gelardi, M; Porro, G; Quaranta, N; Quaranta, V; Study Group On CRSwNP, I, 2020)
" The coexistence of CRS, bronchial asthma and aspirin intolerance (aspirin triad) is an adverse prognostic factor with higher risk of recurrences."3.91Analysis of the impact of bronchial asthma and hypersensitivity to aspirin on the clinical course of chronic sinusitis with nasal polyps. ( Dąbrowska, K; Fendler, W; Pagacz, K; Pietruszewska, W; Podwysocka, M, 2019)
"Background Aspirin-exacerbated respiratory disease (AERD), also known as Samter's triad or aspirin (ASA)-intolerant asthma, affects 7% of asthmatics and has a higher prevalence in those with chronic rhinosinusitis and concomitant nasal polyposis."3.88Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease. ( Waldram, JD; Walters, KM; White, AA; Woessner, KM, 2018)
" We also demonstrated that hypereosinophilia, asthma, and aspirin intolerance may increase the OR differently in eosinophilic patients."3.85Prognostic value of nasal cytology and clinical factors in nasal polyps development in patients at risk: can the beginning predict the end? ( Autilio, C; Baroni, S; Battista, M; De Corso, E; De Vita, C; Galli, J; Lucidi, D; Paludetti, G; Romanello, M, 2017)
" Aspirin-exacerbated respiratory disease (AERD) is defined as asthma, chronic rhinosinusitis with nasal polyposis, and hypersensitivity to cyclooxygenase-1 inhibitors."3.85Immunoglobulin G4 sinusitis in association with aspirin-exacerbated respiratory disease. ( Johal, K; Peters, A; Welch, K, 2017)
"Aspirin hypersensitivity associated with chronic rhinosinusitis-with or without nasal polyposis-and asthma resistant to conventional therapy defines the aspirin-exacerbated respiratory disease (AERD)."3.85Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria. ( Cutrera, R; Di Marco, A; Porcaro, F, 2017)
"Oral aspirin challenge (OAC) reveals aspirin-exacerbated respiratory disease (AERD) in approximately 50% of unselected patients with chronic rhinosinusitis with nasal polyposis (CRSwNP)."3.85Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study. ( Gudziol, V; Hummel, T; Koschel, D; Michel, M; Sonnefeld, C, 2017)
" In our previous studies, we showed that the TNFA -308A allele is a genetic predisposition factor in a subgroup of aspirin-sensitive (ASA+) CRS patients suffering from nasal polyps (NP) in the Hungarian population."3.81A conserved linkage group on chromosome 6, the 8.1 ancestral haplotype, is a predisposing factor of chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarians. ( Bella, Z; Hirschberg, A; Kadocsa, E; Kemény, L; Kiricsi, Á; Polyánka, H; Révész, M; Szabó, K; Szabó, Z; Széll, M; Vóna, I, 2015)
"Aspirin-exacerbated respiratory disease (AERD), formerly known as Samter's Triad, is a syndrome of airway inflammation characterized by rhinosinusitis with polyposis, asthma, and nonsteroidal anti-inflammatory drug (NSAID) intolerance."3.81Samter's Triad to Aspirin-Exacerbated Respiratory Disease: Historical Perspective and Current Clinical Practice. ( Krouse, HJ; Krouse, JH, 2015)
"To demonstrate that quality-of-life outcomes after endoscopic sinus surgery are not compromised in patients with Samter's triad (asthma, nasal polyps, aspirin sensitivity) when compared to patients with eosinophilic chronic rhinosinusitis with nasal polyposis (eCRSwP) who are not aspirin sensitive."3.80Aspirin sensitivity does not compromise quality-of-life outcomes in patients with Samter's triad. ( Comer, BT; Jang, DW; Kountakis, SE; Lachanas, VA, 2014)
" CRSwNP was subdivided into allergic fungal rhinosinusitis (AFRS), aspirin-exacerbated respiratory disease (AERD), and other CRSwNP."3.80Impact of vitamin D deficiency upon clinical presentation in nasal polyposis. ( Mulligan, JK; Schlosser, RJ; Schmedes, GW; Soler, ZM; Storck, K, 2014)
"Samter's triad is a well described condition manifesting as chronic rhinosinusitis with nasal polyposis, asthma and aspirin intolerance in a non-atopic individual."3.80Samter's triad with aural involvement: a novel approach to management. ( Heywood, R; Narula, A; Sethukumar, P, 2014)
" The impact of surgery and factors such as the presence of polyps, asthma, and aspirin sensitivity on the bacterial state are poorly understood."3.79The bacteriology of chronic rhinosinusitis and the pre-eminence of Staphylococcus aureus in revision patients. ( Bassiouni, A; Cleland, EJ; Wormald, PJ, 2013)
"Aspirin-exacerbated respiratory disease (AERD) is distinguished from aspirin-tolerant asthma/chronic sinusitis in large part by an exuberant infiltration of eosinophils that are characterized by their overexpression of metabolic pathways that drive the constitutive and aspirin-induced secretion of cysteinyl leukotrienes (CysLTs)."3.79Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease. ( Borish, L; Huyett, P; Liu, L; Negri, J; Payne, SC; Steinke, JW, 2013)
"Patients with chronic rhinosinusitis (CRS) and nasal polyps (NPs) may be subdivided into aspirin-sensitive (AS) and aspirin-tolerant (AT) populations."3.79Characterization and treatment of patients with chronic rhinosinusitis and nasal polyps. ( Fountain, CR; Katial, RK; Kingdom, TT; Mudd, PA; Ramakrishnan, VR; Sillau, SH, 2013)
"SPINK5 single-nucleotide polymorphisms (SNPs) and SPINK5 expression levels were correlated with CRS without (CRSsNP) and with nasal polyps (CRSwNP), aspirin intolerance, asthma, and allergies."3.78Low SPINK5 expression in chronic rhinosinusitis. ( Brieger, J; Fruth, K; Goebel, G; Gosepath, J; Koutsimpelas, D; Mann, WJ; Schmidtmann, I, 2012)
"Chronic rhinosinusitis (CRS) with nasal polyposis (NP) may be associated with hypersensitivity to nonsteroidal anti-inflammatory drugs, representing a syndrome of aspirin-exacerbated respiratory disease (AERD)."3.78Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4. ( Celejewska-Wójcik, N; Cybulska, A; Hartwich, P; Hydzik-Sobocińska, K; Januszek, R; Mastalerz, L; Nieckarz, R; Oleś, K; Sanak, M; Stręk, P; Szaleniec, J; Wójcik, K, 2012)
"Aspirin-exacerbated respiratory disease (AERD) is a unique syndrome of airway inflammation that frequently occurs in patients with nasal polyposis, chronic sinusitis, and asthma."3.78Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization. ( Stevenson, DD; White, AA, 2012)
"The present study inluded 22 patients presenting either with very severe or moderately severe aspirin triad 17 of whom suffered exacerbation of chronic polypous suppurative rhinosinusitis."3.77[The treatment of polypous suppurative rhinosinusitis in the patients presenting with the severe and moderate aspirin triad]. ( Riabova, MA; Shumilova, NA, 2011)
"There is a well-recognized association of aspirin sensitivity, aspirin-induced asthma, nasal polyposis or sinusitis, known as Samter's triad."3.76Aspirin sensitivity and the nose. ( Douglas, GC; Karkos, PD; Swift, AC, 2010)
"It was the aim of this study to investigate the prevalence of otologic manifestations in a cohort of Samter's syndrome patients (nasal polyps with chronic rhinosinusitis, aspirin intolerance and asthma)."3.75Otologic manifestations in Samter's syndrome. ( Caversaccio, M; Häusler, R; Helbling, A, 2009)
"Among the patients with asthma, polymorphism at -1082A/G was significantly associated with the phenotype of aspirin-intolerant asthma, AIA (P = 0."3.75Combined effect of IL-10 and TGF-beta1 promoter polymorphisms as a risk factor for aspirin-intolerant asthma and rhinosinusitis. ( Cho, BY; Kim, SH; Lee, HN; Park, HS; Yang, EM; Ye, YM, 2009)
"Airway eosinophilia is a hallmark of aspirin-sensitive asthma/rhinitis."3.75Chemokine CC-ligand 5 production and eosinophil activation into the upper airways of aspirin-sensitive patients. ( Fuentes-Beltrán, A; García-Cruz, Mde L; Montes-Vizuet, R; Negrete-García, MC; Teran, LM; Valencia-Maqueda, E, 2009)
" Severe uncontrolled allergic rhinitis, nonallergic rhinitis, chronic rhinosinusitis, aspirin-exacerbated respiratory diseases, or occupational airway diseases are defined as SCUADs."3.75Unmet needs in severe chronic upper airway disease (SCUAD). ( Bachert, C; Bousquet, J; Canonica, GW; Casale, TB; Cruz, AA; Lockey, RJ; Zuberbier, T, 2009)
"Without prior exposure to aspirin or NSAIDs, the chance of a positive OAC was 5 in 12 (42%) but was 198 in 231 (86%) for those with a history of aspirin- and NSAID-associated asthma attacks."3.74Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. ( Dursun, AB; Karasoy, D; Simon, RA; Stevenson, DD; Woessner, KA, 2008)
" Often it is associated with non allergic rhinitis with eosinophilia syndrome (NARES), nasal polyposis and intolerance to Aspirin and NSAID's."3.74[Nonallergic diseases of the upper and lower airways]. ( Menz, G; Rothe, T, 2008)
" In these cases, CRS tends to be associated with bronchial asthma (BA), especially, aspirin-intolerant asthma (AIA)."3.74Correlation between the prostaglandin D(2)/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma. ( Haruna, S; Moriyama, H; Otori, N; Yoshikawa, M; Yoshimura, T, 2008)
"Rhinosinusitis is highly associated with aspirin-intolerant asthma (AIA)."3.74Association between a TGFbeta1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients. ( Holloway, JW; Kim, SH; Park, CS; Park, HS; Shin, HD, 2007)
"Aspirin desensitization is indicated for patients who have aspirin-exacerbated respiratory disease and whose asthma and/or rhinosinusitis is suboptimally controlled with inhaled corticosteroids and leukotriene-modifying drugs."3.74Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. ( Bernstein, JA; Castells, MC; Gawchik, SM; Lee, TH; Macy, E; Settipane, RA; Simon, RA; Wald, J; Woessner, KM, 2007)
"We conducted a retrospective study to determine the prevalence of Samter's triad (nasal polyps, asthma, and aspirin sensitivity) in 208 consecutively presenting patients who had undergone functional endoscopic sinus surgery (FESS) for chronic rhinosinusitis from September 2001 through August 2003."3.74The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery. ( Kim, JE; Kountakis, SE, 2007)
" Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis."3.74BSACI guidelines for the management of rhinosinusitis and nasal polyposis. ( Dixon, TA; Drake-Lee, AB; Durham, SR; Huber, PA; Jones, NS; Mirakian, R; Nasser, SM; Ryan, D; Scadding, GK, 2008)
"To identify genes whose expression is most characteristic of chronic rhinosinusitis and aspirin-sensitive asthma through genome-wide transcriptional profiling of nasal polyp tissue."3.74Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma. ( Goldsztein, H; Metson, R; Platt, MP; Reh, DD; Stankovic, KM, 2008)
"Cysteinyl leukotrienes play a disease-regulating role in rhinosinusitis and asthma, particularly aspirin-sensitive disease."3.73Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. ( Corrigan, C; Lee, T; Mallett, K; Parikh, A; Roberts, D; Scadding, G; Ying, S, 2005)
"Data were compared between asthmatic patients who reported exacerbations after aspirin ingestion and those who did not."3.73Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. ( Borish, L; Hunt, J; Mascia, K; Patrie, J; Phillips, CD; Steinke, JW, 2005)
"We have previously demonstrated that aspirin triggers specific generation of 15-hydroxyeicosateraenoic acid (15-HETE) from nasal polyp epithelial cells and peripheral blood leukocytes (PBL) from aspirin-sensitive (AS) but not aspirin-tolerant (AT) patients with asthma/rhinosinusitis."3.73Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest). ( Bienkiewicz, B; Cieslak, M; Dubuske, L; Grzegorczyk, J; Jedrzejczak, M; Kowalski, ML; Pawliczak, R; Ptasinska, A, 2005)
"The blocking effect of controller medications for asthma could have an effect on the outcome of aspirin challenges in patients suspected of having aspirin-exacerbated respiratory disease (AERD)."3.73The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. ( Simon, RA; Stevenson, DD; White, AA, 2005)
"To address the hypothesis that expression of 1 or more EP receptors on nasal mucosal inflammatory cells is deficient in patients with aspirin-sensitive compared with nonaspirin-sensitive polypoid rhinosinusitis."3.73Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. ( Corrigan, CJ; Lee, TH; Meng, Q; Parikh, A; Scadding, G; Ying, S, 2006)
"The urinary leukotriene E4 (U-LTE4) concentration is significantly increased in patients with aspirin-intolerant asthma (AIA)."3.72Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. ( Akiyama, K; Higashi, A; Higashi, N; Ishii, T; Kawagishi, Y; Mita, H; Osame, M; Taniguchi, M, 2004)
"Although many studies have assumed that the overproduction of cysteinyl- leukotrienes (cys-LTs) and an imbalance of arachidonic acid metabolism may be plausible causes for the pathogenesis of aspirin-intolerant asthma (AIA), there has been little experimental evidence to substantiate this notion in lower airways of patients with AIA."3.71A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. ( Akiyama, K; Higashi, N; Mita, H; Osame, M; Taniguchi, M, 2002)
"Patients with aspirin-sensitive rhinosinusitis, which is frequently associated with intrinsic bronchial asthma, can be desensitized by long-term treatment with oral aspirin."3.71Individual monitoring of aspirin desensitization. ( Amedee, RG; Gosepath, J; Mann, WJ; Schaefer, D, 2001)
"Patients with aspirin-hypersensitive rhinosinusitis/asthma suffer from a severe form of hyperplastic rhinosinusitis with recurrent polyposis."3.71Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity. ( Danilewicz, M; Grzegorczyk, J; Kornatowski, T; Kowalski, ML; Pawliczak, R; Wagrowska-Danilewicz, M, 2002)
"The aspirin triad (nasal polyposis, asthma and sensitivity to aspirin) is a well-recognized clinical entity, also known as aspirin-induced asthma (AIA)."3.70Effects of sinus surgery on asthma in aspirin triad patients. ( Higuchi, Y; Kawasaki, M; Nakamura, H; Takahashi, S, 1999)
"This study confirms the importance of eosinophil infiltration in the pathogenesis of severe or recurrent nasal polyps based on allergy and aspirin intolerance."3.70[Significance of eosinophilic granulocytes in relation to allergy and aspirin intolerance in patients with sinusitis polyposa]. ( Bittinger, F; Gosepath, J; Kaldenbach, T; Klimek, L; Mann, WJ; Schäfer, D, 1999)
"The high prevalence of aspirin intolerance in asthmatics and patients with nasal polyps as well as reports of familial clustering suggest a genetic disposition of this disease."3.70[Family study of patients with aspirin intolerance and rhinosinusitis]. ( Langenbeck, U; May, A; Wagner, D; Weber, A, 2000)
" In contrast, the sinusitis of the aspirin triad syndrome is often fulminate, expansive, and recurrent, and complications may be more frequent."3.69Orbital complications of sinusitis in the aspirin triad syndrome. ( Massaro, BM; McFadden, EA; Toohill, RJ; Woodson, BT, 1996)
"Aspirin-sensitive patients with asthma experience continuous inflammation of their nasal and sinus tissues, complicated by recurrent sinusitis, which frequently leads to asthma attacks."3.69Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. ( Christiansen, SC; Hankammer, MA; Mathison, DA; Simon, RA; Stevenson, DD, 1996)
"We attempted to determine the relationship of nasal polyps to histamine (HA) metabolism."3.68Histamine metabolism in nasal polyps. ( Abe, Y; Fukui, H; Harada, T; Imamura, I; Irifune, M; Matsunaga, T; Ogino, S, 1993)
" ASA challenges were performed in 17 ASA-sensitive patients with asthma and rhinosinusitis, and tryptase and histamine levels were measured in their venous blood samples."3.68Tryptase and histamine release during aspirin-induced respiratory reactions. ( Bosso, JV; Schwartz, LB; Stevenson, DD, 1991)
"An 11-year retrospective study was conducted to evaluate the surgical treatment of sinusitis in aspirin-triad patients."3.68Surgery for sinusitis and aspirin triad. ( Fink, JN; Kany, RJ; McFadden, EA; Toohill, RJ, 1990)
"One hundred seven known aspirin (ASA)-sensitive patients with rhinosinusitis-asthma were studied from 1975 to 1988."3.68Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma. ( Mathison, DA; Simon, RA; Stevenson, DD; Sweet, JM, 1990)
" Before immunotherapy, all patients had a complete evaluation of the severity of asthma by symptom-medication scores and a pulmonary function test, as well as a study of other triggering factors by checking on seasonal and perennial allergens, sinusitis, and other possible causes, such as aspirin intolerance; 196 patients were investigated between 9 and 12 months after the onset of the survey by means of pulmonary function tests and symptom-medication scores."3.67Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. ( Bousquet, J; Clauzel, AM; Dhivert, H; Guérin, B; Hejjaoui, A; Michel, FB; Skassa-Brociek, W, 1988)
"Nearly 700 specimens of polyps and sinus tissues from 12 patients with asthma and aspirin idiosyncrasy were studied with histochemical and immunofluorescent immunoglobulin techniques."3.67Histopathology and immunofluorescent immunoglobulins in asthmatics with aspirin idiosyncrasy. ( Carr, R; English, GM; Farr, R; Spector, S, 1987)
"Seventy-four asthmatic patients seen in a hospital were challenged with aspirin."3.67Prevalence of aspirin intolerance in asthmatics treated in a hospital. ( Castillo, JA; Picado, C, 1986)
"This study attempted to determine whether or not nasal and sinus surgery had a beneficial or deleterious effect upon the asthma of patients with nasal polyps and aspirin idiosyncrasy."3.67Nasal polypectomy and sinus surgery in patients with asthma and aspirin idiosyncrasy. ( English, GM, 1986)
"In order to determine the types of respiratory responses observed during aspirin-induced reactions, 50 consecutive asthmatic patients with a history of aspirin sensitivity underwent prospective oral aspirin challenges between 1979 and 1981."3.66Aspirin-sensitive rhinosinusitis/asthma: spectrum of adverse reactions to aspirin. ( Mathison, DA; Pleskow, WW; Schatz, M; Simon, RA; Stevenson, DD; Zeiger, RS, 1983)
"Aspirin-sensitive asthma is not well documented in children."3.66Aspirin-induced asthma in children. ( Collins-Williams, C; Tan, Y, 1982)
"Chronic rhinosinusitis with nasal polyposis may be a symptom of aspirin-intolerance."3.65[Rhinosinusitis polyposa as the only symptom of aspirin intolerance -- a rhinorheomanometric diagnosis (author's transl)]. ( Enzmann, H; Kühn, H, 1977)
" We conducted network meta-analysis of sinusitis symptoms, heath-related quality of life, rescue oral corticosteroids and surgery, endoscopic and radiologic scores, and adverse events."2.82Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. ( Bousquet, J; Brignardello-Petersen, R; Chu, DK; Kennedy, DW; Oykhman, P; Paramo, FA, 2022)
"Rhinosinusitis is among the most common infectious complications of humoral immunodeficiency, which is not uncommon in patients with refractory CRS."2.46Rhinosinusitis and comorbidities. ( Brooks, EG; Ryan, MW, 2010)
"Chronic rhinosinusitis is often associated with bronchial asthma."2.45[Chronic rhinosinusitis in morbus widal: clinical aspects and therapeutic options]. ( Jung, H, 2009)
"Rhinosinusitis is among the most common infectious complications of humoral immunodeficiency, and humoral immunodeficiency is not uncommon in patients with refractory chronic rhinosinusitis."2.44Diseases associated with chronic rhinosinusitis: what is the significance? ( Ryan, MW, 2008)
"Eosinophilia is frequently, but not exclusively, caused by immunoglobulin (Ig)E-mediated hypersensitivity and is dominated by the associated cytokine milieu of Th2 inflammation."2.43Differential diagnosis of eosinophilic chronic rhinosinusitis. ( Ferguson, BJ; Sok, JC, 2006)
"Sinusitis is very common, so it is important to understand its pathophysiology, diagnosis, and medical and surgical treatments."2.43Sinusitis: allergies, antibiotics, aspirin, asthma. ( Radojicic, C, 2006)
"Ifetroban was well tolerated in AERD and did not change the mean 2-point increase in Total Nasal Symptom Score (P = ."1.91Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease. ( Boyce, JA; Buchheit, KM; Cahill, KN; Chen, CC; Cho, L; Cui, J; Feng, C; Hacker, J; Israel, E; Laidlaw, TM; Le, M, 2023)
"Aspirin treatment after desensitization (ATAD) represents an effective therapeutic option suitable for NSAID-exacerbated respiratory disease (N-ERD) patients with recalcitrant disease."1.72A retrospective study on long-term efficacy of intranasal lysine-aspirin in controlling NSAID-exacerbated respiratory disease. ( Andrews, PJ; Pendolino, AL; Scadding, GK; Scarpa, B, 2022)
"Treatment of aspirin-exacerbated respiratory disease (AERD) includes endoscopic sinus surgery (ESS) and aspirin desensitization (AD) with aspirin therapy after desensitization (ATAD)."1.62Major complications of aspirin desensitization and maintenance therapy in aspirin-exacerbated respiratory disease. ( Adappa, ND; Bosso, JV; Civantos, AM; Corr, AM; Gleeson, PK; Ig-Izevbekhai, KI; Kohanski, MA; Kumar, A; Lin, TC; Locke, TB; Palmer, JN; Sweis, AM, 2021)
" Long-term administration of acetylsalicylic acid (ASA) after desensitization has been used to mitigate these sequelae, but the optimal dose and balancing symptom relief and side effects remain unsettled."1.56Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid. ( Appel, H; Greve, J; Hahn, J; Hoffmann, TK; Lindemann, J; Petereit, F; Scheithauer, MO; Sommer, F; Veit, JA, 2020)
"Aspirin sensitivity has a highly significant association with AFRS."1.48Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. ( Ahmed, S; Almeyda, R; Anari, S; Carrie, S; Cathcart, R; Clark, A; Coombes, E; Erskine, S; Farboud, A; Hobson, J; Hopkins, C; Jervis, P; Kara, N; Khalil, H; Kumar, N; Mansell, N; Panesaar, J; Philpott, C; Philpott, CM; Prinsley, P; Ray, J; Robertson, A; Salam, M; Sunkaraneni, S; Sunkaraneni, V; Wilson, A; Woods, J, 2018)
"Prednisone was the most common OCS prescribed."1.46Oral corticosteroid prescribing habits for rhinosinusitis: The American Rhinologic Society membership. ( Ernst, HM; Rotenberg, BW; Rudmik, L; Scott, JR; Sowerby, LJ, 2017)
"Sinusitis is both prevalent and costly, affecting more than 14% of the population and costing more than $3."1.30Medical management of sinusitis. ( Kaliner, M, 1998)
"Tissue eosinophilia was a prominent feature of both allergic and nonallergic CHS/NP and correlated in both subgroups with the density of GM-CSF and IL-3 mRNA+ cells."1.29Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis. ( Bean, DK; Cunningham, L; Hamid, Q; Hamilos, DL; Leung, DY; Schotman, E; Wood, R; Yasruel, Z, 1995)
"of our patients with bronchial asthma."1.27[Inhalation provocation test with lysine acetylsalicylic acid (Aspisol)--a useful method for the diagnosis of analgesic asthma]. ( Kirsten, D; Meister, W; Treutler, D, 1984)

Research

Studies (264)

TimeframeStudies, this research(%)All Research%
pre-199030 (11.36)18.7374
1990's17 (6.44)18.2507
2000's62 (23.48)29.6817
2010's78 (29.55)24.3611
2020's77 (29.17)2.80

Authors

AuthorsStudies
Pendolino, AL1
Scadding, GK3
Scarpa, B1
Andrews, PJ1
Oykhman, P2
Paramo, FA1
Bousquet, J3
Kennedy, DW2
Brignardello-Petersen, R1
Chu, DK3
Bertlich, M1
Ihler, F1
Bertlich, I1
Weiss, BG1
Gröger, M2
Haubner, F1
D'Souza, GE1
Nwagu, U1
Barton, B1
Unsal, AA1
Rabinowitz, MR1
Rosen, MR1
Nyquist, GG1
Cohn, J1
Most, J1
Toskala, EM1
Sehanobish, E3
Asad, M2
Jerschow, E4
Talat, R1
Gengler, I1
Phillips, KM1
Caradonna, DS1
Gray, ST1
Sedaghat, AR2
Idler, BM1
Lal, D1
Marino, MJ1
Patel, P1
Bensko, JC9
Bhattacharyya, N2
Laidlaw, TM17
Buchheit, KM14
Wallace, DV1
Ramos, CL1
Woessner, KM4
Stevens, WW4
White, AA12
Cahill, KN9
Wu, P2
Milne, GL1
Amin, T1
Singer, J2
Murphy, K1
Lewis, E2
Gapko, D1
Boyce, JA4
Tan, LH1
Lin, C1
Ungerer, H1
Kumar, A3
Qatanani, A1
Adappa, ND6
Palmer, JN6
Bosso, JV9
Reed, D1
Cohen, NA3
Kohanski, MA6
Miss Ozuna, L1
Ryan, T1
Mullur, J3
Steger, CM1
Gakpo, D4
Maurer, R3
Corey, KB2
Turner, JH1
Chowdhury, NI1
Chandra, RK1
Li, P1
Bangert, C1
Villazala-Merino, S1
Fahrenberger, M1
Krausgruber, T1
Bauer, WM1
Stanek, V1
Campion, NJ1
Bartosik, T1
Quint, T1
Regelsberger, G1
Niederberger-Leppin, V1
Bock, C1
Schneider, S1
Eckl-Dorna, J1
Sohail, A1
Hacker, J2
Taliaferro, F1
Ordovas-Montanes, J2
Tchekmedyian, R1
Lundberg, M1
Pitlick, MM1
Pongdee, T1
Suikkila, A1
Lyly, A1
Hafrén, L1
Saarinen, R1
Klockars, T1
McGill, A1
Palumbo, M1
Ghiasi, Y1
Wangberg, H2
Bagsic, SRS1
White, A2
Walters, BK1
Hagan, JB1
Divekar, RD1
Willson, TJ1
Stokken, JK1
Pinheiro-Neto, CD1
O'Brien, EK1
Choby, G1
Esmaeilzadeh, H2
Zare, M1
Alyasin, S1
Nabavizadeh, H1
Mortazavi, N2
Kanannejad, Z1
Rank, MA2
Bognanni, A1
Bernstein, JA2
Ellis, AK1
Golden, DBK1
Greenhawt, M1
Horner, CC1
Ledford, DK1
Lieberman, J1
Luong, AU1
Orlandi, RR1
Samant, SA1
Shaker, MS1
Soler, ZM2
Stukus, DR1
Wang, J1
Peters, AT2
Perić, A3
Gaćeša, D2
Cvetković, G1
Vojvodić, D1
Tao, M1
Roberts, S1
Arnold, M1
Candelo, E1
McCalla, M1
Valderrama, OA1
Avila-Castano, K1
Chelf, C1
Olomu, O1
Donaldson, AM1
Hayashi, H2
Fukutomi, Y2
Mitsui, C2
Kajiwara, K2
Watai, K2
Tomita, Y1
Kamide, Y2
Tsuburai, T1
Sekiya, K2
Ishii, M1
Hasegawa, Y1
Taniguchi, M5
Alfallaj, R1
Obaid, SB1
Almousa, H1
Ismail, D1
Mahjoub, S1
Alanazy, F1
Dousary, SA1
Alromaih, S1
Aloulah, M1
Alrasheed, A1
Alroqi, AS1
Alsaleh, S1
Cho, L1
Cui, J1
Feng, C1
Chen, CC1
Le, M1
Israel, E1
Lee, Y1
Kim, C1
Lee, E1
Lee, HY1
Woo, SD1
You, SC1
Park, RW1
Park, HS3
Supron, AD1
Bergmark, RW1
Roditi, RE1
Panara, K1
Grose, E2
Lee, DJ2
Safadi, J1
Douglas, JE1
Lee, JM2
Adame, MJ1
Raji, M1
Shan, Y1
Zhang, Y1
Kuo, YF1
Tripple, JW1
Herzberg, SD1
Bosso, AM1
Sangal, NR1
Badrani, JH1
Cavagnero, K1
Eastman, JJ1
Kim, AS1
Strohm, A1
Yan, C1
Deconde, A1
Zuraw, BL1
Christiansen, SC2
Doherty, TA1
Kim, SL1
Vukadinović, T1
Vuksanović Božarić, A1
Vukomanović Đurđević, B1
Radunović, M1
Lee, SE1
Farquhar, DR1
Adams, KN1
Masood, MM1
Senior, BA1
Thorp, BD2
Zanation, AM2
Ebert, CS2
San Nicoló, M1
Högerle, C1
Gellrich, D1
Eder, K1
Pfrogner, E1
Wongsa, C1
Sompornrattanaphan, M1
Tantilipikorn, P1
Thongngarm, T1
Podwysocka, M1
Dąbrowska, K1
Fendler, W1
Pagacz, K1
Pietruszewska, W1
Nelson, RK1
Bush, A1
Stokes, J1
Nair, P1
Akuthota, P1
Larivée, N1
Chin, CJ1
Studer, MB1
Roland, LT1
Ochsner, MC1
Cox, D1
DelGaudio, JM1
Wise, SK1
Levy, JM6
Kshirsagar, RS1
Chou, DW1
Wei, J1
Liang, J1
Dwyer, DF1
Katz, HR1
Vukovic, M1
Lai, J1
Bankova, LG1
Shalek, AK1
Barrett, NA2
Hahn, J1
Appel, H1
Scheithauer, MO1
Petereit, F1
Greve, J1
Lindemann, J1
Hoffmann, TK1
Veit, JA1
Sommer, F1
McHugh, T1
Levin, M1
Snidvongs, K1
Banglawala, SM1
Sommer, DD4
Vandenberghe-Dürr, S1
Landis, BN1
Jandus, P1
Chen, YS1
Yip, J1
Cottrell, J1
Sykes, J1
Lee, JK1
Gelardi, M1
Porro, G1
Quaranta, V1
Quaranta, N1
Cassano, M1
Ciprandi, G1
Study Group On CRSwNP, I1
Schlosser, RJ2
Malfitano, MJ1
Santarelli, GD1
Gelpi, M1
Brown, WC1
Stepp, WH1
Hernandez, S1
Kimple, AJ1
Sweis, AM2
Locke, TB2
Ig-Izevbekhai, KI1
Lin, TC2
Gleeson, PK2
Civantos, AM2
Corr, AM2
Gakpo, DH1
Buchheit, K1
Parhar, HS1
Salmon, MK1
Jakiela, B1
Soja, J1
Sladek, K1
Przybyszowski, M1
Plutecka, H2
Gielicz, A3
Rebane, A1
Bochenek, G2
Cameli, P1
D'Alessandro, M1
Bergantini, L1
Silvestri, E1
Romaldi, A1
Emmi, G1
Parronchi, P1
Bargagli, E1
He, SC1
Xu, YT1
Baptist, AP1
Borish, L4
Campo, P1
Cho, SH1
Keswani, A1
Nanda, A1
Espersen, J1
Weber, U1
Römer-Franz, A1
Lenarz, T1
Stolle, SRO1
Warnecke, A1
Cook, KA2
Domissy, A1
Simon, RA12
Modena, BD1
Tripathi, SH1
Bavaro, N1
Mittal, A1
Spierling Bagsic, SR1
Sowerby, LJ3
Patel, KB1
Schmerk, C1
Rotenberg, BW2
Rocha, T1
Kuruvilla, M1
Bensko, J1
Arshi, S2
Darougar, S1
Nabavi, M2
Bemanian, MH2
Fallahpour, M2
Shokri, S1
Ahmadian, J1
Molatefi, R1
Rekabi, M1
Moinfar, Z1
Hashemitari, P1
Eslami, N1
Barbi, M1
Porcelli, SA1
Haque, R1
Jackson, DJ1
Hopkins, C4
Priyadharshini, VS1
Jiménez-Chobillon, MA1
de Graaf, J1
Porras Gutiérrez de Velasco, R1
Gratziou, C1
Ramírez-Jiménez, F1
Teran, LM3
De Corso, E1
Lucidi, D1
Battista, M1
Romanello, M1
De Vita, C1
Baroni, S1
Autilio, C1
Galli, J1
Paludetti, G1
Johal, K1
Welch, K1
Peters, A1
Ranasinghe, VJ1
Trope, M1
Brooks, SG1
Glicksman, JT1
Parasher, AK1
Rodríguez-Jiménez, JC1
Moreno-Paz, FJ1
Guaní-Guerra, E1
Walters, KM1
Waldram, JD3
Philpott, CM1
Erskine, S2
Kumar, N2
Anari, S2
Kara, N2
Sunkaraneni, S1
Ray, J2
Clark, A2
Wilson, A1
Philpott, C1
Robertson, A1
Ahmed, S1
Carrie, S1
Sunkaraneni, V1
Jervis, P1
Panesaar, J1
Farboud, A1
Cathcart, R1
Almeyda, R1
Khalil, H1
Prinsley, P1
Mansell, N1
Salam, M1
Hobson, J1
Woods, J1
Coombes, E1
Yamaguchi, T1
Ishii, T2
Yamamoto, K1
Higashi, N4
Okamoto, M1
Weinstein, SF1
Katial, RK5
Bardin, P1
Korn, S1
McDonald, M1
Garin, M1
Bateman, ED1
Hoyte, FCL1
Germinaro, M1
Eid, RC1
Palumbo, ML1
DeGregorio, GA1
Laidlaw, T1
Kowalski, ML9
Stevenson, DD18
Cooper, T1
Greig, SR1
Zhang, H1
Seemann, R1
Wright, ED1
Vliagoftis, H1
Côté, DWJ1
Rusznak, M1
Peebles, RS1
Kuhn, DM1
Kovačević, SV1
Barać, A1
Perić, AV1
Jožin, SM1
Förster-Ruhrmann, U1
Behrbohm, W1
Pierchalla, G1
Szczepek, AJ1
Fluhr, JW1
Olze, H1
Ono, E1
Mita, H3
Cleland, EJ1
Bassiouni, A1
Wormald, PJ2
Mullol, J2
Picado, C3
Karakaya, G1
Celebioglu, E1
Kalyoncu, AF1
Jang, DW1
Comer, BT1
Lachanas, VA1
Kountakis, SE3
Steinke, JW2
Liu, L2
Huyett, P1
Negri, J1
Payne, SC1
Kutlu, A1
Salihoglu, M1
Haholu, A1
Cesmeci, E1
Cincik, H1
Ozturk, S1
Edward, JA1
Sanyal, M1
Ramakrishnan, VR3
Le, W1
Nguyen, AL1
Kingdom, TT3
Hwang, PH2
Nayak, JV2
Fountain, CR2
Mudd, PA1
Sillau, SH2
Bobolea, I1
Cabañas, R1
Jurado-Palomo, J1
Fiandor, A1
Quirce, S1
McCarty, JC1
Ferguson, BJ4
Schmedes, GW1
Storck, K1
Mulligan, JK1
Klimek, L3
Dollner, R1
Pfaar, O1
Parikh, A4
Świerczyńska-Krępa, M2
Sanak, M6
Stręk, P2
Ćmiel, A1
Szczeklik, A4
Niżankowska-Mogilnicka, E3
Montone, KT1
Cho, KS1
Soudry, E1
Psaltis, AJ1
Nadeau, KC1
McGhee, SA1
Machado-Carvalho, L1
Roca-Ferrer, J1
Hoffbauer, S1
Au, M1
Gupta, MK1
Nayan, S2
Sethukumar, P1
Heywood, R1
Narula, A1
Dazy, KM2
Matsusaka, M1
Kabata, H1
Fukunaga, K1
Suzuki, Y1
Masaki, K1
Mochimaru, T1
Sakamaki, F1
Oyamada, Y1
Inoue, T1
Oguma, T1
Sayama, K1
Koh, H1
Nakamura, M1
Umeda, A1
Ono, J1
Ohta, S1
Izuhara, K1
Asano, K1
Betsuyaku, T1
DeConde, AS1
Suh, JD1
Mace, JC1
Alt, JA1
Smith, TL3
Aryan, Z1
Makowska, J1
Lewandowska-Polak, A2
Wojtczak, A1
Skrętkowicz, J1
Szabó, K1
Polyánka, H1
Kiricsi, Á1
Révész, M1
Vóna, I1
Szabó, Z1
Bella, Z1
Kadocsa, E1
Kemény, L1
Széll, M1
Hirschberg, A1
Pezato, R1
Holtappels, G2
De Ruyck, N1
Derycke, L1
Van Crombruggen, K1
Bachert, C5
Pérez-Novo, CA1
Zhang, L1
Gevaert, P3
Krouse, HJ1
Krouse, JH2
Gitomer, SA1
Getz, AE1
Adelman, J1
McLean, C1
Shaigany, K1
Makowska, JS1
Olszewska-Ziąber, A1
Bieńkiewicz, B3
Kurowski, M1
Woźniakowski, B1
Rotkiewicz, A1
Dunn, NM1
Rebelo, J1
Choong, K1
Fulford, M1
Chan, A1
Sakalar, EG1
Muluk, NB1
Kar, M1
Cingi, C1
Porcaro, F1
Di Marco, A1
Cutrera, R1
Schleimer, RP1
Gudziol, V1
Michel, M1
Sonnefeld, C1
Koschel, D1
Hummel, T1
Scott, JR1
Ernst, HM1
Rudmik, L1
Dursun, AB1
Woessner, KA1
Karasoy, D1
Einecke, U1
Rothe, T1
Menz, G2
Williams, AN1
Yoshimura, T1
Yoshikawa, M1
Otori, N1
Haruna, S1
Moriyama, H1
Caversaccio, M1
Häusler, R1
Helbling, A1
Das, S1
Maeso, PA1
Becker, AM1
Prosser, JD1
Adam, BL1
Kim, SH2
Yang, EM1
Lee, HN1
Cho, BY1
Ye, YM1
Fuentes-Beltrán, A1
Montes-Vizuet, R1
Valencia-Maqueda, E1
Negrete-García, MC1
García-Cruz, Mde L1
Leunig, A1
Braunschweig, F1
Havel, M1
Markmann, S1
Kramer, M1
Platt, M1
Metson, R2
Stankovic, K1
Canonica, GW1
Casale, TB1
Cruz, AA1
Lockey, RJ1
Zuberbier, T1
Jung, H1
Cardona, R1
Ramírez, RH1
Reina, Z1
Escobar, MF1
Morales, E1
Schachtel, BP1
Voelker, M1
Sanner, KM1
Gagney, D1
Bey, M1
Schachtel, EJ1
Becka, M1
Ryan, MW2
Brooks, EG1
Wood, AJ1
Douglas, RG1
Strand, M1
Prasertsuntarasai, T1
Leung, R1
Zheng, W1
Alam, R1
Douglas, GC1
Karkos, PD1
Swift, AC1
Rizk, H1
Riabova, MA1
Shumilova, NA1
Fruth, K1
Goebel, G1
Koutsimpelas, D1
Gosepath, J4
Schmidtmann, I1
Mann, WJ4
Brieger, J1
Celejewska-Wójcik, N1
Mastalerz, L2
Wójcik, K1
Nieckarz, R1
Januszek, R1
Hartwich, P1
Szaleniec, J1
Hydzik-Sobocińska, K1
Oleś, K1
Cybulska, A1
Li, H1
Shan, Z1
Wang, B1
Shikani, AH1
Kourelis, K1
Rohayem, Z1
Basaraba, RJ1
Leid, JG1
Osame, M2
Akiyama, K2
Sousa, AR1
Scadding, G3
Corrigan, CJ2
Lee, TH3
Arm, JP1
Austen, KF1
Rosado, A1
Vives, R1
González, R1
Rodríguez, J1
DUGAS, M1
MILLER, J1
ABRUZZI, WA1
DE VARENNE, D1
Kiełbasa, B1
Kawagishi, Y1
Higashi, A1
Van Zele, T2
Watelet, JB1
Claeys, G1
Claeys, C1
van Cauwenberge, P2
Amrol, D1
Murray, JJ1
Corrigan, C1
Mallett, K1
Ying, S2
Roberts, D1
Lee, T1
Mascia, K1
Patrie, J1
Hunt, J1
Phillips, CD1
Koga, T1
Oshita, Y1
Kamimura, T1
Koga, H1
Aizawa, H1
Ptasinska, A1
Jedrzejczak, M1
Cieslak, M1
Grzegorczyk, J2
Pawliczak, R2
Dubuske, L1
Meng, Q1
Lee, JY1
Sok, JC2
Radojicic, C1
Holloway, JW1
Shin, HD1
Park, CS1
Gawlewicz, A1
Faber, J1
Smith, WB1
Macy, E1
Castells, MC1
Gawchik, SM1
Settipane, RA1
Wald, J1
Robinson, JL1
Griest, S1
James, KE1
Zhang, N1
Patou, J1
Slavin, RG2
Kim, JE1
Browne, JP1
Slack, R1
Lund, V1
Brown, P1
Durham, SR1
Mirakian, R1
Jones, NS1
Drake-Lee, AB1
Ryan, D1
Dixon, TA1
Huber, PA1
Nasser, SM1
Joe, SA1
Thakkar, K1
Stankovic, KM1
Goldsztein, H1
Reh, DD1
Platt, MP1
Grevers, G1
Pleskow, WW3
Mathison, DA7
Lumry, WR3
Schatz, M2
Zeiger, RS3
Kirsten, D1
Meister, W1
Treutler, D1
Curd, JG2
Enzmann, H2
Rieben, FW1
Tan, Y1
Collins-Williams, C1
Schapowal, AG1
Simon, HU1
Schmitz-Schumann, M1
Hamilos, DL1
Leung, DY1
Wood, R1
Cunningham, L1
Bean, DK1
Yasruel, Z1
Schotman, E1
Hamid, Q1
Swierczyński, Z1
Samoliński, B1
Krzeski, A1
Ogino, S1
Abe, Y1
Irifune, M1
Harada, T1
Matsunaga, T1
Imamura, I1
Fukui, H1
Sliwinska-Kowalska, M1
Igarashi, Y1
White, MV1
Wojciechowska, B1
Brayton, P1
Kaulbach, H1
Rozniecki, J1
Kaliner, MA1
McFadden, EA2
Woodson, BT1
Massaro, BM1
Toohill, RJ3
Hankammer, MA1
Dias, MA1
Biedlingmaier, JF1
Kaliner, M1
Atamuradov, MA1
Garaev, TA1
Nakamura, H1
Kawasaki, M1
Higuchi, Y1
Takahashi, S1
Ulualp, SO1
Sterman, BM1
Kaldenbach, T1
Schäfer, D1
Bittinger, F1
Amar, YG1
Frenkiel, S1
Sobol, SE1
Kordek, P1
Studniarek, M1
Kośny, B1
May, A1
Wagner, D1
Langenbeck, U1
Weber, A1
Babu, KS1
Salvi, SS1
Siepmann, M1
Kirch, W1
Schaefer, D1
Amedee, RG1
Stern, A1
Mardiney, M1
Nizankowska, E1
Swierczynska, M1
Kornatowski, T1
Wagrowska-Danilewicz, M1
Danilewicz, M1
Kühn, H1
Spector, SL1
Wangaard, CH1
Farr, RS1
Lockey, RF1
Faidi, AR1
Tan, EM1
Vaughan, JH1
Stenius, BS1
Lemola, M1
Schwartz, LB1
Kany, RJ1
Fink, JN1
Sweet, JM1
Knight, A1
Jankowski, R1
Béné, MC1
Moneret-Vautrin, AD1
Haas, F1
Faure, G1
Simon, C1
Wayoff, M1
Hejjaoui, A1
Clauzel, AM1
Guérin, B1
Dhivert, H1
Skassa-Brociek, W1
Michel, FB1
English, GM2
Spector, S1
Farr, R1
Carr, R1
Castillo, JA1
Siegel, SC1
Rachelefsky, GS1
Gorichkina, LA1
Frolova, MK1
Kuria, VF1
Davis, SL1
Hadley, RA1
Nilsson, DC1
Stahl, RH1
Debray, H1
Galland, A1
Settipane, GA1
Chafee, FH1
Klein, DE1
McDonald, JR1

Clinical Trials (21)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Low Dietary Salicylate on Biochemical Markers of Aspirin Exacerbated Respiratory Disease[NCT01778465]7 participants (Actual)Interventional2013-05-31Completed
Moving Towards PREcision Medicine In United Airways Disease: Unraveling inflaMmatory Patterns in Asthmatic Patients With or Without Nasal Polyps (PREMIUM) - a Descriptive Pilot Study[NCT05009758]30 participants (Anticipated)Interventional2021-09-01Recruiting
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma[NCT01287039]Phase 3489 participants (Actual)Interventional2011-04-30Completed
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma[NCT01285323]Phase 3464 participants (Actual)Interventional2011-03-31Completed
Dupilumab as add-on Therapy for Aspirin-exacerbated Respiratory Disease (AERD)[NCT03595488]Phase 211 participants (Actual)Interventional2018-09-05Completed
Improving Patient Care Via Proteomics Based, Microbe-Specific Detection of Chronic Rhinosinusitis[NCT00962689]38 participants (Actual)Observational2009-08-31Completed
Challenge Test for Acetylsalicylic Acid Hypersensitivity[NCT01681615]50 participants (Anticipated)Interventional2012-09-30Not yet recruiting
"Real Life Proof-of-Concept Study to Assess the Effect of Methylcellulose as add-on Seal to the In-season Pharmacologic Rescue Treatment in Subjects With Allergic Rhinitis"[NCT02557269]Phase 460 participants (Actual)Interventional2015-05-31Active, not recruiting
The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases[NCT01867281]Phase 432 participants (Actual)Interventional2013-06-30Completed
Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis[NCT03472144]Phase 360 participants (Anticipated)Interventional2017-07-07Recruiting
Role of Doxycycline in the Management of Patients With Chronic Rhinosinusitis With Nasal Polyps[NCT05157412]Phase 360 participants (Anticipated)Interventional2022-03-01Not yet recruiting
Retrospective Review on Patients With Recurrent Asthmatic Attacks Requiring Hospitalizations[NCT04479501]2,280 participants (Actual)Observational2017-12-01Completed
A 3 Year Longitudinal Study of the Level of Asthma Control and Treatment of Asthma Patients in Hong Kong[NCT03239431]400 participants (Anticipated)Observational [Patient Registry]2017-09-15Recruiting
Determinants of Surgical Outcomes in Chronic Sinusitis[NCT00799097]516 participants (Actual)Observational2004-07-31Completed
Effect of Thymoquinone and Olive Oil on Wound Healing After Endoscopic Sinus Surgery in Patients With Nasal Polyposis[NCT06070311]50 participants (Anticipated)Interventional2023-10-31Not yet recruiting
Role of Short Term Systemic Corticosteroid Therapy in the Management of Chronic Rhinosinusitis Without Nasal Polyps[NCT01676415]Phase 49 participants (Actual)Interventional2012-08-31Terminated (stopped due to participants are no longer receiving intervention due to clinical logistics)
High Volume Saline Irrigation in the Post-operative Management of Chronic Rhinosinusitis: A Multicenter Randomized Single-Blind Controlled Trial[NCT02636959]Early Phase 120 participants (Anticipated)Interventional2015-12-31Recruiting
Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP). Can Shedding of Epithelial Barrier Proteins be Used as Biomarker in Severe Asthma With/Out CRSwNP Manageme[NCT05365841]85 participants (Anticipated)Observational2022-05-15Not yet recruiting
Ideal Frequency of Postoperative High Volume Saline Irrigations Following Endoscopic Sinus Surgery[NCT01680705]75 participants (Actual)Interventional2012-07-31Completed
Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps.[NCT05143502]Phase 1/Phase 260 participants (Anticipated)Interventional2022-01-01Active, not recruiting
Randomized, Double-blinded, Placebo-controlled, Prospective, Multicenter Trial to Evaluate the Efficacy and Safety of SIC in Subjects With Mild/Moderate Asthma and Rhinitis/Rhinoconjunctivitis Sensitized to D.Pteronyssinus and/or D. Farinae[NCT04435990]Phase 3150 participants (Anticipated)Interventional2020-10-06Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Sino-Nasal Outcome Test (SNOT-22)

"The Sino-Nasal Outcome Test (SNOT-22) is a validated 22-item Chronic rhinosinusitis-specific instrument which is scored using a scale where 0=No problem, 1=Very mild problem, 2=Mild or slight problem, 3=Moderate problem, 4=Severe problem, and 5=Problem as bad as it can be. Higher scores on the SNOT-22 survey items suggest worse patient functioning or symptom severity (total score range: 0-110)" (NCT01778465)
Timeframe: 14 days after commencement

Interventionscore on a scale (Median)
Low Salicylate Diet44
Normal Diet66

Urinary Creatinine Levels

(NCT01778465)
Timeframe: 14 days after commencement

Interventionmmol/L (Median)
Low Salicylate Diet9.9
Normal Diet15.3

Urinary Levels of Cys-Leukotrienes

(NCT01778465)
Timeframe: 14 days after commencement

Interventionpg/ml (Median)
Low Salicylate Diet874.05
Normal Diet771.99

Urinary Salicylic Acid Levels

(NCT01778465)
Timeframe: 14 days after enrollment

Interventionng/ml (Median)
Low Salicylate Diet0.6
Normal Diet0.92

Urinary Salicyluric Acid Levels

(NCT01778465)
Timeframe: 14 days after commencement

Interventionng/ml (Median)
Low Salicylate Diet44.21
Normal Diet23.82

Change From Baseline in Asthma Control Questionnaire (ACQ) Over 16 Weeks Using Mixed Model for Repeated Measures

"The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control. The during treatment (Weeks 4, 8, 12 and 16) average ACQ was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16

Interventionunits on a scale (Least Squares Mean)
Placebo-0.676
Reslizumab 3.0 mg/kg-0.941

Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) to Week 16

"The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were patient-specific, which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.~Positive change from baseline scores indicate improvement in quality of life." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Week 16

Interventionunits on a scale (Least Squares Mean)
Placebo0.695
Reslizumab 3.0 mg/kg0.933

Change From Baseline in Asthma Symptom Utility Index (ASUI) Over 16 Weeks Using Mixed Model for Repeated Measures

"The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms.~The during treatment (Weeks 4, 8, 12 and 16) average ASUI was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Positive change from baseline values indicate improvement in asthma symptoms. Information was obtained from questionnaire about asthma symptoms." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16

Interventionunits on a scale (Least Squares Mean)
Placebo0.109
Reslizumab 3.0 mg/kg0.167

Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Model for Repeated Measures

"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer. Positive change from baseline scores indicate improvement in asthma control.~The during treatment (Weeks 4, 8, 12 and 16) average FEV1 was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16

Interventionliters (Least Squares Mean)
Placebo0.110
Reslizumab 3.0 mg/kg0.248

Change From Baseline in Short-Acting Beta-Agonist (SABA) Use Over 16 Weeks Using Mixed Model for Repeated Measures

"SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit patients were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.~The during treatment (Weeks 4, 8, 12 and 16) SABA use was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16

Interventionpuffs/day (Least Squares Mean)
Placebo-0.36
Reslizumab 3.0 mg/kg-0.64

Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment

"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization CAEs were adjudicated by committee to assure consistency.~Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01287039)
Timeframe: Day 1 to Week 52

InterventionCAEs in 52 weeks (Mean)
Placebo1.804
Reslizumab 3.0 mg/kg0.904

Kaplan-Meier Estimates for Time to First Clinical Asthma Exacerbation (CAE)

"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. The distributions were compared by a log rank test stratified by baseline usage of oral corticosteroid (yes or no) and geographical region (US or other)." (NCT01287039)
Timeframe: Day 1 to Day 478 (longest treatment time plus 2 weeks)

Interventionweeks (Median)
Placebo34.9
Reslizumab 3.0 mg/kgNA

Participants With a Positive Anti-Reslizumab Antibody Status During Study

The immunogenicity of reslizumab was assessed by measuring for the presence of anti-reslizumab antibodies at baseline, weeks 16, 32, 48, and 52 or early withdrawal. Blood samples for anti-reslizumab antibodies assessment were also obtained from all patients (inside or outside of the US) experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms. (NCT01287039)
Timeframe: Weeks 16, 32, 48 and 52

Interventionparticipants (Number)
Reslizumab 3.0 mg/kg8

Change From Baseline in Blood Eosinophil Count Over 16 Weeks and 52 Weeks Using Mixed Model for Repeated Measures

"Blood eosinophil counts were measured using a standard complete blood count (CBC) with differential blood test at each scheduled visit, and from all patients experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms.~The during treatment average eosinophil counts were estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline values correlate to reduced asthma severity." (NCT01287039)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early withdrawal

,
Intervention10^9 blood eosinophil/L (Least Squares Mean)
Over first 16 weeksOver 52 weeks
Placebo-0.118-0.127
Reslizumab 3.0 mg/kg-0.584-0.582

Frequency of Each of the Two Criteria for Clinical Asthma Exacerbations (CAEs)

"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. Adjusted CAE rate and confidence intervals for the two criteria were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01287039)
Timeframe: Day 1 to Week 52

,
InterventionCAEs in 52 weeks (Mean)
Requiring systemic corticosterioids >3 daysRequiring hospitalization or ER visit
Placebo1.6040.207
Reslizumab 3.0 mg/kg0.7220.137

Participants With Treatment-Emergent Adverse Events

An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01287039)
Timeframe: Day 1 (post-dose) to Week 65. The last postbaseline value for approximately 20 patients in each

,
Interventionparticipants (Number)
At least 1 AEMild severity AEModerate severity AESevere AETreatment-related AETreatment-related mild AETreatment-related moderate AETreatment-related severe AEAE causing patient discontinuationSerious AEDeaths
Placebo206411333236231308341
Reslizumab 3.0 mg/kg19768107223624934240

Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Abnormal Lab Values

"Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology, and urinalysis values.~Significance criteria:~Blood urea nitrogen: >=10.71 mmol/L~Uric acid: M>=625, F>=506 μmol/L~Aspartate aminotransferase: >=3*upper limit of normal (ULN). Normal range is 10-43 U/L~Alanine aminotransferase: >=3*ULN. Normal range is 10-40 U/L~GGT = gamma-glutamyl transpeptidase: >= 3*ULN. Normal range is 5-49 U/L.~Bilirubin: >=34.2 μmol/L~White blood cells: <=3.0 or >20 10^9/L~Hemoglobin: M<=115, F<=95 g/dL~Hematocrit: M<0.37, F<0.32 L/L~Neutrophils: <=1.0 10^9/L~Eosinophils: >10.0 %~Platelets: <75 or >=700 10^9/L~Urinalysis: blood, glucose, ketones and total protein: >=2 unit increase from baseline" (NCT01287039)
Timeframe: Week 4 to Week 65. The last postbaseline value for approximately 20 patients in each

,
Interventionparticipants (Number)
Blood urea nitrogenUric acidAspartate aminotransferaseAlanine aminotransferaseGamma-glutamyl transpeptidaseBilirubinWhite blood cells - lowWhite blood cells - highHemoglobinHematocritNeutrophilsEosinophilsPlatelets - lowPlatelets - highUrinalysis - Blood (hemoglobin)Urinalysis - KetonesUrinalysis - GlucoseUrinalysis - Protein
Placebo991312265798135123241132
Reslizumab 3.0 mg/kg8615121634663202151434

Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Vital Signs Values

"Data represents participants with potentially clinically significant (PCS) vital sign values.~Significance criteria~Sitting pulse - high 12-17 yr: >100 and increase of >= 30 beats/minute (bpm)~Sitting pulse - low >=18 yr: <50 and decrease of >=30 bpm~Sitting pulse - high >=18 yr: >100 and increase of >=30 bpm~Sitting systolic blood pressure - low >=18 yr: <90 and decrease of >=30 mmHg~Sitting systolic blood pressure - high >=18 yr: >160 and increase of >=30 mmHg~Sitting diastolic blood pressure - low 12-17 yr: <55 and decrease of >=12 mmHg~Sitting diastolic blood pressure - low >=18 yr: <50 and decrease of >=12 mmHg~Sitting diastolic blood pressure - high >=18 yr: >100 and increase of >=12 mmHg~Respiratory rate >=18 yr: >24 and increase of >=10 breaths/minute~Body temperature - low 12-17 yr: <96.5° Fahrenheit or <35.8° Celsius~Body temp - low >=18 yr: <96.5° F or <35.8° C~Body temp - high >=18 yr: >100.5° Fahrenheit" (NCT01287039)
Timeframe: Week 4 to Week 65. The last postbaseline value for approximately 20 patients in each

,
Interventionparticipants (Number)
Sitting pulse - high 12-17 yrSitting pulse - low >=18 yrSitting pulse - high >=18 yrSitting systolic blood pressure - low >=18 yrSitting systolic blood pressure - high >=18 yrSitting diastolic blood pressure - low 12-17 yrSitting diastolic blood pressure - low >=18 yrSitting diastolic blood pressure - high >=18 yrRespiratory rate >=18 yrBody temperature - low 12-17 yrBody temperature - low >=18 yrBody temperature - high >=18 yr
Placebo11527101031540
Reslizumab 3.0 mg/kg1075701521491

Change From Baseline in Asthma Control Questionnaire (ACQ) Over 16 Weeks Using Mixed Model for Repeated Measures

"The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control. The during treatment (Weeks 4, 8, 12 and 16) average ACQ was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16

Interventionunits on a scale (Least Squares Mean)
Placebo-0.660
Reslizumab 3.0 mg/kg-0.857

Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) to Week 16

"The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were patient-specific, which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.~Positive change from baseline scores indicate improvement in quality of life." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Week 16

Interventionunits on a scale (Least Squares Mean)
Placebo0.777
Reslizumab 3.0 mg/kg0.987

Change From Baseline in Asthma Symptom Utility Index (ASUI) Over 16 Weeks Using Mixed Model for Repeated Measures

"The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms.~The during treatment (Weeks 4, 8, 12 and 16) average ASUI was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Positive change from baseline values indicate improvement in asthma symptoms. Information was obtained from questionnaire about asthma symptoms." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16

Interventionunits on a scale (Least Squares Mean)
Placebo0.080
Reslizumab 3.0 mg/kg0.115

Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) At Week 16

"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer.~Positive change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Week 16

Interventionliters (Least Squares Mean)
Placebo0.122
Reslizumab 3.0 mg/kg0.223

Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Model for Repeated Measures

"FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer. During study (Weeks 4, 8, 12 and 16) average value used a mixed effect model for repeated measures (MMRM) with treatment group, visit, treatment and visit interaction, and stratification factors as fixed effects and participant as a random effect. Covariates for baseline values were also included in the model; for pulmonary function test analyses, covariates for height and sex were included as well.~Positive change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16

Interventionliters (Least Squares Mean)
Placebo0.094
Reslizumab 3.0 mg/kg0.187

Change From Baseline in Short-Acting Beta-Agonist (SABA) Use Over 16 Weeks Using Mixed Model for Repeated Measures

"SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit patients were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.~The during treatment (Weeks 4, 8, 12 and 16) average SABA use was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.~Negative change from baseline scores indicate improvement in asthma control." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16

InterventionSABA puffs per day (Least Squares Mean)
Placebo-0.44
Reslizumab 3.0 mg/kg-0.50

Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment

"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01285323)
Timeframe: Day 1 to Month 12

InterventionCAEs in 52 weeks (Mean)
Placebo2.115
Reslizumab 3.0 mg/kg0.859

Kaplan-Meier Estimates for Time to First Clinical Asthma Exacerbation (CAE)

"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.~CAEs were adjudicated by committee to assure consistency. The distributions were compared by a log rank test stratified by baseline usage of oral corticosteroid (yes or no) and geographical region (US or other)." (NCT01285323)
Timeframe: Day 1 to Day 526 (longest treatment time plus 2 weeks)

Interventionweeks (Median)
PlaceboNA
Reslizumab 3.0 mg/kgNA

Change From Baseline in Blood Eosinophil Count Over 16 Weeks and 52 Weeks Using Mixed Model for Repeated Measures

"The blood eosinophil counts were measured using a standard complete blood count (CBC) with differential blood test. Results of all differential blood tests conducted after randomization were blinded.~The during treatment average eosinophil count was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements. The 'over 16 weeks' value used data from Weeks 4, 8, 12 and 16. The 'over 52 weeks' value used all the during study time points listed in the Time Frame field.~Negative change from baseline values correlate to reduced asthma severity." (NCT01285323)
Timeframe: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early withdrawal

,
Intervention10^9 blood eosinophil/L (Least Squares Mean)
Over first 16 weeksOver 52 weeks
Placebo-0.076-0.076
Reslizumab 3.0 mg/kg-0.555-0.565

Frequency of Each of the Two Criteria for Clinical Asthma Exacerbations (CAEs)

"An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:~use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.~asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization CAEs were adjudicated by committee to assure consistency.~Adjusted CAE rate and confidence intervals for the two criteria were based on Negative Binomial regression model adjusted for stratification factors.~Results are offered as adjusted means." (NCT01285323)
Timeframe: Day 1 to Month 12

,
InterventionCAEs in 52 weeks (Mean)
Requiring systemic corticosterioids >3 daysRequiring hospitalization or ER visit
Placebo1.6600.047
Reslizumab 3.0 mg/kg0.6460.033

Participants With a Positive Anti-Reslizumab Antibody Status During Study

Counts of participants with a positive anti-drug antibody (ADA) response during treatment is offered for the experimental treatment arm. Blood samples were collected for determination of ADAs before study drug infusion. (NCT01285323)
Timeframe: Baseline visit (prior to reslizumab exposure), Weeks 16, 32, 48 and 52

Interventionparticipants (Number)
BaselineWeek 16Week 32Week 48Week 52>=1 positive test result
Reslizumab 3.0 mg/kg101010101015

Participants With Treatment-Emergent Adverse Events TEAE)

An adverse event (AE) was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. (NCT01285323)
Timeframe: Day 1 (post-dose) to Week 65. The endpoint for adverse events was the last postbaseline observation, which included the 90 day follow-up visit.

,
Interventionparticipants (Number)
Any TEAEMild TEAEModerate TEAESevere TEAETreatment-related AEMild treatment-related AEModerate treatment-related AESevere treatment-related AETEAE causing patient discontinuationDeathsSerious AEs
Placebo201361402527141309023
Reslizumab 3.0 mg/kg17767981234221118018

Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Abnormal Lab Values

"Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology (except for eosinophil values), and urinalysis values.~Significance criteria:~Blood urea nitrogen: >=10.71 mmol/L~Creatinine: >=177 μmol/L~Urate: M>=625, F>=506 μmol/L~Aspartate aminotransferase (AST): >=3*upper limit of normal (ULN)~Alanine aminotransferase (ALT): >=3*ULN~GGT = gamma-glutamyl transpeptidase: >= 3*ULN~Total bilirubin: >=34.2 μmol/L~White blood cells (low): <=3.0*10^9/L~White blood cells (high): >=20*10^9/L~Hemoglobin (age >=18 years): M<=115, F<=95 g/dL~Hematocrit (age >=18 years): M<0.37, F<0.32 L/L~Eosinophils/leukocytes: >=10.0%~Platelets: <=75*10^9/L~Neutrophils: <=1.0*10^9/L~Urinalysis: blood, ketones, glucose, and protein: >=2 unit increase from baseline" (NCT01285323)
Timeframe: Week 4 to Week 52

,
Interventionparticipants (Number)
Blood urea nitrogenCreatinineUrateASTALTGGTBilirubinLeukocytes (low)Leukocytes (high)HemoglobinHematocritEosinophils/leukocytesPlateletsNeutrophilsUrine blood (hemoglobin)Urine ketonesUrine glucoseUrine protein
Placebo5053711330510168114286928
Reslizumab 3.0 mg/kg4122393101681019121728

Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Vital Signs Values

"Data represents participants with potentially clinically significant (PCS) vital sign values.~Significance criteria~Sitting pulse (high): >100 and increase of >= 30 beats/minute~Sitting systolic blood pressure (low): <90 and decrease of >= 30 mmHg~Sitting systolic blood pressure (high): >160 and increase of >= 30 mmHg~Sitting diastolic blood pressure (low): <50 and decrease of >=12 mmHg (if 12-17 years old: <55 and decrease of >=12 mmHg 0~Sitting diastolic blood pressure (high): >100 and increase of >=12 mmHg~Respiratory rate (low): <6 breaths/minute~Respiratory rate (high): >24 and increase of >=10 breaths/minute~Body temperature (low): <35.8° Celsius~Body temperature (high): >=38.1 and increase of >=1.1° Celsius" (NCT01285323)
Timeframe: Week 4 to Week 52

,
Interventionparticipants (Number)
>=1 postbaseline vital sign abnormalitySitting pulse (high)Sitting systolic blood pressure (low)Sitting systolic blood pressure (high)Sitting diastolic blood pressure (low)Sitting diastolic blood pressure (high)Respiratory rate (low)Respiratory rate (high)Body temperature (low)Body temperature (high)
Placebo586204304501
Reslizumab 3.0 mg/kg496113415390

Medication Side-effect and Compliance Inventory

The medication side-effect and compliance inventory is a questionnaire to evaluate the frequency and severity of common side effects associated with the medications used in this study. (NCT01676415)
Timeframe: 4-6 weeks and 3 months after initiation of treatment

InterventionParticipants (Count of Participants)
Prednisone0
Topical Mometasone0

Taskforce Symptom Inventory

Change from baseline in individual symptom severity. The taskforce symptom inventory is a visual analog scale of the severity of the 4 major symptoms making up the clinical diagnostic criteria of CRS. (NCT01676415)
Timeframe: 4-6 weeks and 3 months after initiation of treatment

InterventionParticipants (Count of Participants)
Prednisone0
Topical Mometasone0

SNOT-22 Questionnaire

"The Sino-nasal Outcome Test-22 is a validated questionnaire that measures 22 nasal and quality of life symptoms (nasal obstruction and loss of smell and taste) ranked from 0 (not a problem) to 5 (problem as bad as it can be).~Min score= 0, Max score= 110 (worst possible problem on all symptoms)~Change from baseline of the SNOT-22 score. The SNOT-22 questionnaire is a 22-item disease-specific health related quality of life instrument validated for use in chronic rhinosinusitis." (NCT01676415)
Timeframe: 4-6 weeks and 3 months after initiation of treatment

,
Interventionunits on a scale (Mean)
4-6 WEEKS3 MONTHS
Prednisone45.7549
Topical Mometasone34.434.4

Reviews

65 reviews available for aspirin and Sinusitis

ArticleYear
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis.
    The Journal of allergy and clinical immunology, 2022, Volume: 149, Issue:4

    Topics: Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Aspirin; Chronic Disease; Humans; Nasa

2022
New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease.
    Current opinion in allergy and clinical immunology, 2022, 02-01, Volume: 22, Issue:1

    Topics: Aspirin; Asthma, Aspirin-Induced; Basophils; Humans; Nasal Polyps; Sinusitis

2022
Treatment options for chronic rhinosinusitis with nasal polyps.
    Allergy and asthma proceedings, 2021, 11-01, Volume: 42, Issue:6

    Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Aspirin; Asthma; Biological Products; Chronic Diseas

2021
Updates on treatment options in aspirin exacerbated respiratory disease.
    Current opinion in allergy and clinical immunology, 2022, 02-01, Volume: 22, Issue:1

    Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Cytokines; Humans; Sinusitis

2022
Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease-How to Choose.
    The journal of allergy and clinical immunology. In practice, 2022, Volume: 10, Issue:6

    Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Desensitization, Immunologic

2022
Aspirin-Exacerbated Respiratory Disease: A Unique Case of Drug Hypersensitivity.
    Immunology and allergy clinics of North America, 2022, Volume: 42, Issue:2

    Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Sinusitis

2022
Aspirin-Exacerbated Respiratory Disease and the Unified Airway: A Contemporary Review.
    Otolaryngologic clinics of North America, 2023, Volume: 56, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Disease;

2023
A Review of Aspirin-exacerbated Respiratory Diseases and Immunological Efficacy of Aspirin Desensitization.
    Iranian journal of allergy, asthma, and immunology, 2022, Oct-26, Volume: 21, Issue:5

    Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Humans; Nas

2022
Relationship Between Alcohol Intolerance and Aspirin-Exacerbated Respiratory Disease (AERD): Systematic Review.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2023, Volume: 169, Issue:1

    Topics: Aspirin; Asthma, Aspirin-Induced; Cross-Sectional Studies; Desensitization, Immunologic; Humans; Nas

2023
Aspirin-exacerbated respiratory disease: Updates in the era of biologics.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2023, Volume: 131, Issue:3

    Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Humans; Nasal Polyps

2023
The chronic rhinosinusitis practice parameter.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2023, Volume: 131, Issue:3

    Topics: Advisory Committees; Aspirin; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Humans;

2023
Aspirin desensitization therapy in aspirin-exacerbated respiratory disease: a systematic review.
    International forum of allergy & rhinology, 2020, Volume: 10, Issue:4

    Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Nasal Polyps; Rhinitis; Sinu

2020
Comorbidities associated with eosinophilic chronic rhinosinusitis: A systematic review and meta-analysis.
    Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 2020, Volume: 45, Issue:4

    Topics: Aspirin; Asthma; Chronic Disease; Comorbidity; Eosinophilia; Humans; Nasal Polyps; Rhinitis; Severit

2020
[Widal's triad : clinical manifestations, pathophysiology and therapeutic advances].
    Revue medicale suisse, 2020, Apr-08, Volume: 16, Issue:689

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Drug Hypersensitivity; Humans; Nasal Polyp

2020
The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy,
    The Journal of allergy and clinical immunology, 2021, Volume: 147, Issue:3

    Topics: Administration, Oral; Algorithms; Allergens; Animals; Anti-Inflammatory Agents; Aspirin; Asthma, Asp

2021
Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization,

2021
Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease.
    The Journal of allergy and clinical immunology, 2021, Volume: 148, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Humans; Nasal Polyps; Sin

2021
Aspirin exacerbated respiratory disease: Current topics and trends.
    Respiratory medicine, 2018, Volume: 135

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arachidonic Acid; Aspirin; A

2018
Heterogeneity of NSAID-Exacerbated Respiratory Disease: has the time come for subphenotyping?
    Current opinion in pulmonary medicine, 2019, Volume: 25, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biomarkers; Chronic Disea

2019
Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD.
    Allergology international : official journal of the Japanese Society of Allergology, 2019, Volume: 68, Issue:3

    Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Bl

2019
Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease.
    Immunology and allergy clinics of North America, 2013, Volume: 33, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Hypersensitivity; Humans; Nasal Polyps; Respi

2013
Identifying asthma triggers.
    Otolaryngologic clinics of North America, 2014, Volume: 47, Issue:1

    Topics: Allergens; Aspirin; Asthma; Disease Progression; Female; Gastroesophageal Reflux; Humans; Male; Prog

2014
Topical nasal lysine aspirin in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis with nasal polyposis.
    Expert review of clinical immunology, 2014, Volume: 10, Issue:5

    Topics: Administration, Intranasal; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Human

2014
The molecular genetics of inflammatory, autoimmune, and infectious diseases of the sinonasal tract: a review.
    Archives of pathology & laboratory medicine, 2014, Volume: 138, Issue:6

    Topics: Aspirin; Autoimmune Diseases; Churg-Strauss Syndrome; Granulomatosis with Polyangiitis; Humans; Infe

2014
Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity.
    Respiratory research, 2014, Aug-26, Volume: 15

    Topics: Animals; Aspirin; Asthma; Drug Hypersensitivity; Humans; Nasal Polyps; Receptors, Prostaglandin E, E

2014
Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).
    Current allergy and asthma reports, 2015, Volume: 15, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Desensitization, Immunologic; Hum

2015
Aspirin-exacerbated respiratory disease: characteristics and management strategies.
    Expert review of clinical immunology, 2015, Volume: 11, Issue:7

    Topics: Animals; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Nasal Polyps; Rhini

2015
Hypersensitivity to Aspirin and other NSAIDs: Diagnostic Approach in Patients with Chronic Rhinosinusitis.
    Current allergy and asthma reports, 2015, Volume: 15, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Drug Hypersensitivity; Humans; Rh

2015
[Hypersensitivity to acetylsalicylic acid].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2015, Volume: 68, Issue:2

    Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Humans; Incidence; Nasal Polyps; Rhinitis;

2015
Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis.
    The Journal of allergy and clinical immunology, 2015, Volume: 136, Issue:6

    Topics: Adult; Antibodies, Monoclonal, Humanized; Aspirin; Asthma; Comorbidity; DNA, Catalytic; Drug Hyperse

2015
The Role of Surgery in Management of Samter's Triad: A Systematic Review.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2016, Volume: 155, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Drug Hypersensitivity; Endoscopy; Humans;

2016
Chronic Rhinosinusitis and Aspirin-Exacerbated Respiratory Disease.
    Immunology and allergy clinics of North America, 2016, Volume: 36, Issue:3

    Topics: Allergens; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Disease Progre

2016
Aspirin-exacerbated respiratory disease and current treatment modalities.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2017, Volume: 274, Issue:3

    Topics: Algorithms; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, H

2017
Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.
    Immunology and allergy clinics of North America, 2016, Volume: 36, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Humans; Respiratory Tract Disease

2016
Is aspirin desensitization indicated for the treatment recalcitrant chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease?
    The Laryngoscope, 2017, Volume: 127, Issue:4

    Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Humans; Nasal Polyp

2017
Current complications and treatment of aspirin-exacerbated respiratory disease.
    Expert review of respiratory medicine, 2016, Volume: 10, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensit

2016
The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis.
    Current allergy and asthma reports, 2008, Volume: 8, Issue:3

    Topics: Administration, Oral; Aspirin; Chronic Disease; Desensitization, Immunologic; Humans; Lysine; Nasal

2008
Aspirin sensitivity and desensitization for asthma and sinusitis.
    Current allergy and asthma reports, 2009, Volume: 9, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cyclooxygenase Inhibitors; Drug Hypersensi

2009
Gene-expression signatures of nasal polyps associated with chronic rhinosinusitis and aspirin-sensitive asthma.
    Current opinion in allergy and clinical immunology, 2009, Volume: 9, Issue:1

    Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Gene Expression Profiling; Humans; Nasal Po

2009
[Chronic rhinosinusitis in morbus widal: clinical aspects and therapeutic options].
    Praxis, 2009, Nov-18, Volume: 98, Issue:23

    Topics: Adrenal Cortex Hormones; Aspirin; Asthma; Chronic Disease; Desensitization, Immunologic; Drug Hypers

2009
[Allergy and intolerance to nonsteroidal antinflammatory drugs: successful desensitization in three cases].
    Biomedica : revista del Instituto Nacional de Salud, 2009, Volume: 29, Issue:2

    Topics: Adult; Anaphylaxis; Angioedema; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspi

2009
Rhinosinusitis and comorbidities.
    Current allergy and asthma reports, 2010, Volume: 10, Issue:3

    Topics: Anti-Bacterial Agents; Aspirin; Cystic Fibrosis; Humans; Hypersensitivity; Immunity, Humoral; Immuno

2010
Pathogenesis and treatment of chronic rhinosinusitis.
    Postgraduate medical journal, 2010, Volume: 86, Issue:1016

    Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bi

2010
Role of aspirin desensitization in the management of chronic rhinosinusitis.
    Current opinion in otolaryngology & head and neck surgery, 2011, Volume: 19, Issue:3

    Topics: Aspirin; Chronic Disease; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Nasal Polyps;

2011
Aspirin intolerance and the cyclooxygenase-leukotriene pathways.
    Current opinion in pulmonary medicine, 2004, Volume: 10, Issue:1

    Topics: Aspirin; Asthma; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Desensiti

2004
Categorization of eosinophilic chronic rhinosinusitis.
    Current opinion in otolaryngology & head and neck surgery, 2004, Volume: 12, Issue:3

    Topics: Aspergillosis, Allergic Bronchopulmonary; Aspirin; Child; Chronic Disease; Eosinophilia; Eosinophils

2004
Alternative medical treatment strategies for chronic hyperplastic eosinophilic sinusitis.
    Current opinion in otolaryngology & head and neck surgery, 2005, Volume: 13, Issue:1

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antifungal Agents; Aspirin; Chronic Disease; Eosino

2005
Current concepts in therapy of chronic rhinosinusitis and nasal polyposis.
    ORL; journal for oto-rhino-laryngology and its related specialties, 2005, Volume: 67, Issue:3

    Topics: Anti-Bacterial Agents; Antifungal Agents; Aspirin; Chronic Disease; Endoscopy; Eosinophilia; Histami

2005
Differential diagnosis of eosinophilic chronic rhinosinusitis.
    Current allergy and asthma reports, 2006, Volume: 6, Issue:3

    Topics: Animals; Aspirin; Chronic Disease; Diagnosis, Differential; Eosinophilia; Fungi; Humans; Hypersensit

2006
Sinusitis: allergies, antibiotics, aspirin, asthma.
    Cleveland Clinic journal of medicine, 2006, Volume: 73, Issue:7

    Topics: Aspirin; Asthma; Drug Hypersensitivity; Humans; Platelet Aggregation Inhibitors; Rhinitis, Allergic,

2006
Selection of patients for aspirin desensitization treatment.
    The Journal of allergy and clinical immunology, 2006, Volume: 118, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Desensitization, Immunologic; Drug Hyperse

2006
Differential diagnosis of eosinophilic chronic rhinosinusitis.
    Clinical allergy and immunology, 2007, Volume: 19

    Topics: Aspirin; Chronic Disease; Diagnosis, Differential; Eosinophilia; Eosinophils; Humans; Mycoses; Rhini

2007
Aspirin-sensitive rhinosinusitis and asthma.
    Clinical allergy and immunology, 2007, Volume: 19

    Topics: Arachidonic Acid; Aspirin; Asthma; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Infl

2007
Staphylococcus aureus enterotoxins as immune stimulants in chronic rhinosinusitis.
    Clinical allergy and immunology, 2007, Volume: 20

    Topics: Animals; Aspirin; Chronic Disease; Enterotoxins; Humans; Immunoglobulin E; Mice; Nasal Mucosa; Nasal

2007
Medical management of rhinosinusitis comorbidities-asthma, aspirin sensitivity, gastroesophageal reflux, immune deficiencies.
    Clinical allergy and immunology, 2007, Volume: 20

    Topics: Aspirin; Asthma; Drug Hypersensitivity; Eosinophils; Gastroesophageal Reflux; Humans; Immunologic De

2007
Chronic rhinosinusitis and asthma.
    Otolaryngologic clinics of North America, 2008, Volume: 41, Issue:2

    Topics: Aspirin; Asthma; Chronic Disease; Comorbidity; Drug Hypersensitivity; Humans; Lymphocytes; Nasal Muc

2008
Diseases associated with chronic rhinosinusitis: what is the significance?
    Current opinion in otolaryngology & head and neck surgery, 2008, Volume: 16, Issue:3

    Topics: Aspirin; Chronic Disease; Cystic Fibrosis; Humans; Hypersensitivity; Immunocompromised Host; Inciden

2008
Phenomenology, pathogenesis, diagnosis and treatment of aspirin-sensitive rhinosinusitis.
    Acta oto-rhino-laryngologica Belgica, 1995, Volume: 49, Issue:3

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin;

1995
[The classification of nonallergic eosinophilic rhinitis and sinus].
    Otolaryngologia polska = The Polish otolaryngology, 1994, Volume: 48 Suppl 17

    Topics: Age Factors; Aspirin; Asthma; Drug Tolerance; Eosinophils; Humans; Nasal Polyps; Neutrophils; Rhinit

1994
Rhinosinusitis and nasal polyposis in aspirin sensitive and aspirin tolerant patients: are they different?
    Thorax, 2000, Volume: 55 Suppl 2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Humans; Nasal Polyps; R

2000
Aspirin and asthma.
    Chest, 2000, Volume: 118, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acids; Aspirin; Asthma; Bronchial Hyperreactivi

2000
Aspirin-induced rhinitis and asthma.
    Current opinion in allergy and clinical immunology, 2001, Volume: 1, Issue:1

    Topics: Aspirin; Asthma; Eicosanoids; Glutathione Transferase; Humans; Rhinitis; Sinusitis

2001
Sheldon Memorial Lecture. Medical management of nasal polyps and sinusitis.
    The Journal of allergy and clinical immunology, 1991, Volume: 88, Issue:2

    Topics: Adrenal Cortex Hormones; Aspirin; Humans; Nasal Polyps; Sinusitis

1991
Desensitization to aspirin in aspirin-sensitive patients with rhino-sinusitis and asthma: a review.
    The Journal of otolaryngology, 1989, Volume: 18, Issue:4

    Topics: Aspirin; Asthma; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Nasal Polyps; Rhinitis

1989
Continuing medical education. Asthma in infants and children: Part 1.
    The Journal of allergy and clinical immunology, 1985, Volume: 76, Issue:1

    Topics: Airway Resistance; Allergens; Aspirin; Asthma; Asthma, Exercise-Induced; Bronchi; Child; Child, Pres

1985

Trials

16 trials available for aspirin and Sinusitis

ArticleYear
Omalizumab ameliorates extrarespiratory symptoms in patients with aspirin-exacerbated respiratory disease.
    The Journal of allergy and clinical immunology, 2023, Volume: 151, Issue:6

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced;

2023
Effect of low salicylate diet on clinical and inflammatory markers in patients with aspirin exacerbated respiratory disease - a randomized crossover trial.
    Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale, 2021, Apr-23, Volume: 50, Issue:1

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biomarkers; Cross-

2021
The Effect of Aspirin on Moderate to Severe Asthmatic Patients with Aspirin Hypersensitivity, Chronic Rhinosinusitis, and Nasal Polyposis.
    Iranian journal of allergy, asthma, and immunology, 2021, Jun-06, Volume: 20, Issue:3

    Topics: Adult; Anti-Asthmatic Agents; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Double-Blind Method

2021
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:2

    Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies,

2019
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:2

    Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies,

2019
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:2

    Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies,

2019
Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:2

    Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies,

2019
Efficacy of hypertonic (2.3%) sea water in patients with aspirin-induced chronic rhinosinusitis following endoscopic sinus surgery.
    Acta oto-laryngologica, 2019, Volume: 139, Issue:6

    Topics: Adult; Aspirin; China; Chronic Disease; Double-Blind Method; Endoscopy; Female; Humans; Male; Middle

2019
Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study.
    The Journal of allergy and clinical immunology, 2014, Volume: 134, Issue:4

    Topics: Administration, Oral; Adult; Aged; Allergens; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Dise

2014
Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2015, Volume: 152, Issue:1

    Topics: Adult; Aged; Aspirin; Asthma; Cross-Over Studies; Desensitization, Immunologic; Drug Hypersensitivit

2015
Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial.
    Clinical immunology (Orlando, Fla.), 2015, Volume: 160, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, I

2015
Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
    Cytokine, 2016, Volume: 77

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; C

2016
Demonstration of the analgesic efficacy and dose-response of acetylsalicylic acid with pseudoephedrine.
    Journal of clinical pharmacology, 2010, Volume: 50, Issue:12

    Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Aspirin; Common Cold; Dose-Response Relationship, Drug;

2010
The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases.
    The Journal of allergy and clinical immunology, 2010, Volume: 126, Issue:4

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Biomarkers; Chronic Disease;

2010
Topical gel therapy for sinonasal polyposis in Samter's triad: preliminary report.
    The Annals of otology, rhinology, and laryngology, 2012, Volume: 121, Issue:11

    Topics: Administration, Topical; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aspirin; Asth

2012
Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis.
    The New England journal of medicine, 2002, Nov-07, Volume: 347, Issue:19

    Topics: Adult; Aged; Aspirin; Asthma; Biopsy; Desensitization, Immunologic; Down-Regulation; Drug Hypersensi

2002
Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin.
    The Journal of allergy and clinical immunology, 1984, Volume: 73, Issue:4

    Topics: Aspirin; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug Hypersensitivity; Forced Expira

1984
[Point scale quantification of changes in computed tomography of chronic hyperplastic rhinosinusitis].
    Przeglad lekarski, 2000, Volume: 57, Issue:3

    Topics: Adult; Aspirin; Chronic Disease; Humans; Image Processing, Computer-Assisted; Middle Aged; Paranasal

2000
Hypersensitivity to acetylsalicylic acid (ASA) and tartrazine in patients with asthma.
    Clinical allergy, 1976, Volume: 6, Issue:2

    Topics: Adolescent; Adult; Aged; Aging; Airway Obstruction; Aspirin; Asthma; Azo Compounds; Benzenesulfonate

1976

Other Studies

183 other studies available for aspirin and Sinusitis

ArticleYear
A retrospective study on long-term efficacy of intranasal lysine-aspirin in controlling NSAID-exacerbated respiratory disease.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2022, Volume: 279, Issue:5

    Topics: Administration, Intranasal; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Lysine; Nasal

2022
Management of chronic rhinosinusitis with nasal polyps in Samter triad by low-dose ASA desensitization or dupilumab.
    Medicine, 2021, Oct-08, Volume: 100, Issue:40

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Aspirin; Chronic Dis

2021
Outcomes of aspirin exacerbated respiratory disease patients treated with aspirin desensitization and biologics.
    International forum of allergy & rhinology, 2022, Volume: 12, Issue:3

    Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Desensitization, Immunologic

2022
Chronic Rhinosinusitis Outcomes of Patients With Aspirin-Exacerbated Respiratory Disease Treated With Budesonide Irrigations: A Case Series.
    The Annals of otology, rhinology, and laryngology, 2022, Volume: 131, Issue:10

    Topics: Adrenal Cortex Hormones; Aspirin; Asthma, Aspirin-Induced; Budesonide; Chronic Disease; Humans; Nasa

2022
Urinary leukotriene E4 is a biomarker for chronic rhinosinusitis associated with leukotriene dysregulation irrespective of aspirin sensitivity status.
    International forum of allergy & rhinology, 2022, Volume: 12, Issue:5

    Topics: Aspirin; Biomarkers; Chronic Disease; Humans; Leukotriene E4; Leukotrienes; Sinusitis

2022
Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2022, Volume: 128, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin

2022
Mediator production and severity of aspirin-induced respiratory reactions: Impact of sampling site and body mass index.
    The Journal of allergy and clinical immunology, 2022, Volume: 150, Issue:1

    Topics: Aspirin; Asthma, Aspirin-Induced; Body Mass Index; Humans; Leukotriene E4; Respiratory System; Sinus

2022
Steroid affected cytokines in aspirin-exacerbated respiratory disease.
    International forum of allergy & rhinology, 2022, Volume: 12, Issue:10

    Topics: Aspirin; Asthma, Aspirin-Induced; Cytokines; Granulocyte-Macrophage Colony-Stimulating Factor; Human

2022
Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2022, Volume: 128, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Arthralgia; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Hu

2022
Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: Efficacy, tolerability, and patient experience.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2022, Volume: 128, Issue:5

    Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Desensitization, Immunologic; Female; Humans;

2022
Utility of nasal mucus inflammatory profile as a biomarker of nasal polyp regrowth in aspirin-exacerbated respiratory disease.
    The journal of allergy and clinical immunology. In practice, 2022, Volume: 10, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biomarkers; Humans; Mucus

2022
Comprehensive Analysis of Nasal Polyps Reveals a More Pronounced Type 2 Transcriptomic Profile of Epithelial Cells and Mast Cells in Aspirin-Exacerbated Respiratory Disease.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Eosinophilia; Epithelial Cells; Humans; Inflammat

2022
Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.
    The Journal of allergy and clinical immunology, 2022, Volume: 150, Issue:2

    Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Eicosanoids; Humans; Nasal Polyps; Prostaglandins

2022
If aspirin-exacerbated respiratory disease treatment is a jigsaw puzzle, where do the aspirin and biologic pieces go?
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2022, Volume: 128, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biological Products; Huma

2022
Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2022, Volume: 52, Issue:12

    Topics: Anosmia; Aspirin; Asthma, Aspirin-Induced; Female; Humans; Mental Health; Quality of Life; Sinusitis

2022
Hypereosinophilia following aspirin desensitization for aspirin-exacerbated respiratory disease.
    The journal of allergy and clinical immunology. In practice, 2022, Volume: 10, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo

2022
Inheritance of NSAID-Exacerbated Respiratory Disease.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2023, Volume: 168, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Humans; Nasal Pol

2023
Pediatric-onset aspirin-exacerbated respiratory disease: Clinical characteristics, prevalence, and response to dupilumab.
    The journal of allergy and clinical immunology. In practice, 2022, Volume: 10, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin

2022
Type 2 biologics reduce cumulative steroid exposure in aspirin-exacerbated respiratory disease.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2022, Volume: 129, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biological Products; Huma

2022
The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis.
    The Journal of allergy and clinical immunology, 2023, Volume: 151, Issue:2

    Topics: Administration, Intranasal; Adrenal Cortex Hormones; Aspirin; Biological Products; Chronic Disease;

2023
Inflammatory mediators in nasal secretions of patients with nasal polyposis with and without aspirin sensitivity.
    Immunity, inflammation and disease, 2023, Volume: 11, Issue:2

    Topics: Aspirin; Asthma, Aspirin-Induced; Cross-Sectional Studies; Humans; Inflammation Mediators; Nasal Pol

2023
Algorithmic Identification of Patients With Aspirin-Exacerbated Respiratory Disease Using an Electronic Health Record.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2023, Volume: 169, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Electronic Health Records

2023
Demographic and clinical profile of patients with chronic rhinosinusitis in Saudi Arabia.
    Saudi medical journal, 2023, Volume: 44, Issue:4

    Topics: Aspirin; Asthma; Chronic Disease; Cross-Sectional Studies; Female; Humans; Male; Nasal Polyps; Preva

2023
Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease.
    The Journal of allergy and clinical immunology, 2023, Volume: 152, Issue:3

    Topics: Animals; Aspirin; Asthma, Aspirin-Induced; Dinoprostone; Eicosanoids; Homeostasis; Humans; Leukotrie

2023
Long-term clinical outcomes of aspirin-exacerbated respiratory disease: Real-world data from an adult asthma cohort.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2023, Volume: 53, Issue:9

    Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Eosinophilia; Eosinophils; Humans; Sinusitis

2023
Perioperative mepolizumab in aspirin-exacerbated respiratory disease does not prevent nasal polyp regrowth.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2023, Volume: 131, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal

2023
Readability and quality analysis of patient education materials in aspirin-exacerbated respiratory disease.
    International forum of allergy & rhinology, 2023, Volume: 13, Issue:12

    Topics: Aspirin; Asthma, Aspirin-Induced; Comprehension; Humans; Patient Education as Topic; Sinusitis

2023
Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data.
    The journal of allergy and clinical immunology. In practice, 2023, Volume: 11, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Cardiovascular Di

2023
Eosinophilic granulomatosis with polyangiitis presenting as aspirin-exacerbated respiratory disease.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2023, Volume: 131, Issue:4

    Topics: Aspirin; Asthma, Aspirin-Induced; Churg-Strauss Syndrome; Granulomatosis with Polyangiitis; Humans;

2023
Lower serum 15-HETE level predicts nasal ILC2 accumulation during COX-1 inhibition in AERD.
    The Journal of allergy and clinical immunology, 2023, Volume: 152, Issue:5

    Topics: Aspirin; Asthma, Aspirin-Induced; Cyclooxygenase Inhibitors; Eicosanoids; Humans; Hydroxyeicosatetra

2023
Angiogenesis and eosinophilia in the nasal mucosa of patients with different clinical phenotypes of chronic rhinosinusitis.
    Journal of infection in developing countries, 2023, 10-31, Volume: 17, Issue:10

    Topics: Aspirin; Chronic Disease; Cross-Sectional Studies; Eosinophilia; Humans; Nasal Mucosa; Nasal Polyps;

2023
Effect of Zileuton Treatment on Sinonasal Quality of Life in Patients with Aspirin-Exacerbated Respiratory Disease.
    American journal of rhinology & allergy, 2019, Volume: 33, Issue:6

    Topics: Adult; Aged; Allergens; Anti-Asthmatic Agents; Arachidonate 5-Lipoxygenase; Aspirin; Asthma, Aspirin

2019
A graduated approach to management of chronic rhinosinusitis in aspirin-exacerbated respiratory disease in the era of precision medicine.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2019, Volume: 123, Issue:4

    Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Humans; Precision Medicine; Sinusitis

2019
The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2020, Volume: 277, Issue:2

    Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Bodily Secretions; Chronic Disease; Cytokines; Desensitizat

2020
Clinical characteristics and aspirin desensitization in Thai patients with a suggestive history of NSAID-exacerbated respiratory disease.
    Asian Pacific journal of allergy and immunology, 2022, Volume: 40, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Desensitization, Immunologic; Human

2022
Analysis of the impact of bronchial asthma and hypersensitivity to aspirin on the clinical course of chronic sinusitis with nasal polyps.
    Otolaryngologia polska = The Polish otolaryngology, 2019, Oct-16, Volume: 73, Issue:5

    Topics: Adult; Aspirin; Asthma; Bronchial Hyperreactivity; Case-Control Studies; Drug Hypersensitivity; Fema

2019
Eosinophilic Asthma.
    The journal of allergy and clinical immunology. In practice, 2020, Volume: 8, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Biomarkers; Child; Humans; Hypersensitivit

2020
Aspirin-Exacerbated Respiratory Disease With Allergic Fungal Rhinosinusitis: A Case Series of Overlapping Sinonasal Endotypes.
    American journal of rhinology & allergy, 2020, Volume: 34, Issue:3

    Topics: Allergens; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Female;

2020
Aspirin-exacerbated respiratory disease: longitudinal assessment of a large cohort and implications of diagnostic delay.
    International forum of allergy & rhinology, 2020, Volume: 10, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Delayed Diagnosis; Humans

2020
IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.
    The Journal of allergy and clinical immunology, 2020, Volume: 145, Issue:6

    Topics: Adult; Aged; Antibodies; Aspirin; Female; Humans; Immunoglobulin E; Immunoglobulin G; Interleukin-5;

2020
Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid.
    American journal of rhinology & allergy, 2020, Volume: 34, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensit

2020
A retrospective analysis of bronchiectasis in patients with aspirin-exacerbated respiratory disease.
    The journal of allergy and clinical immunology. In practice, 2020, Volume: 8, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Bronchiectasis; Humans; R

2020
Surgical outcomes in aspirin-exacerbated respiratory disease without aspirin desensitization.
    International forum of allergy & rhinology, 2020, Volume: 10, Issue:10

    Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Endoscopy; Humans; Nasal Polyps; Retrospective St

2020
Clinical-Cytological-Grading and phenotyping in patients with chronic rhinosinusitis with nasal polyps: the relevance in clinical practice.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2020, Jun-23, Volume: 90, Issue:2

    Topics: Adult; Aspirin; Asthma; Cell Biology; Chronic Disease; Comorbidity; Cross-Sectional Studies; Female;

2020
Aspirin-exacerbated respiratory disease: personalized medical and surgical approaches.
    International forum of allergy & rhinology, 2020, Volume: 10, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo

2020
A Comparison of Sphenoid Sinus Osteoneogenesis in Aspirin-Exacerbated Respiratory Disease.
    American journal of rhinology & allergy, 2021, Volume: 35, Issue:2

    Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal Polyps; Retrospective Studies; Rhin

2021
Major complications of aspirin desensitization and maintenance therapy in aspirin-exacerbated respiratory disease.
    International forum of allergy & rhinology, 2021, Volume: 11, Issue:2

    Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Nasal Polyps; Retrospective

2021
Leukotriene-Associated Rash in Aspirin-Exacerbated Respiratory Disease.
    The journal of allergy and clinical immunology. In practice, 2020, Volume: 8, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Exanthema; Humans; Leukot

2020
Age as a factor in treatment of aspirin-exacerbated respiratory disease: relationship to required aspirin maintenance dose after desensitization.
    International forum of allergy & rhinology, 2020, Volume: 10, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo

2020
Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease.
    The Journal of allergy and clinical immunology, 2021, Volume: 147, Issue:4

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Biomarkers; Bronchoalveolar L

2021
A multicenter approach to evaluate omalizumab effectiveness in Samter's triad.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2020, Aug-06, Volume: 90, Issue:3

    Topics: Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma

2020
[Aspirin-exacerbated respiratory disease: current diagnosis and treatment].
    Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery, 2020, Nov-07, Volume: 55, Issue:11

    Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Respiratory Tract Diseases;

2020
Level of sex hormones and their association with acetylsalicylic acid intolerance and nasal polyposis.
    PloS one, 2020, Volume: 15, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Cone-Beam Computed Tomography; Drug Hypers

2020
Dysbiosis in aspirin-exacerbated respiratory disease.
    International forum of allergy & rhinology, 2021, Volume: 11, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Dysbiosi

2021
Multidisciplinary single-center outcomes compared to two-center outcomes for the treatment of aspirin exacerbated respiratory disease.
    The journal of allergy and clinical immunology. In practice, 2021, Volume: 9, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Humans; Respiratory Tract

2021
Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5Rα in a real-world setting.
    The journal of allergy and clinical immunology. In practice, 2021, Volume: 9, Issue:7

    Topics: Antibodies, Monoclonal, Humanized; Aspirin; Humans; Sinusitis

2021
Perioperative management and perceived risks of sinus surgery in patients with aspirin-exacerbated respiratory disease.
    International forum of allergy & rhinology, 2021, Volume: 11, Issue:7

    Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal Polyps; Rhinitis; Sinusitis

2021
COVID-19 in a series of patients with aspirin-exacerbated respiratory disease.
    The journal of allergy and clinical immunology. In practice, 2021, Volume: 9, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; COVID-19; Humans; Respira

2021
Epithelial dysregulation in chronic rhinosinusitis with nasal polyposis (CRSwNP) and aspirin-exacerbated respiratory disease (AERD).
    The Journal of allergy and clinical immunology, 2021, Volume: 148, Issue:5

    Topics: Aspirin; Biomarkers; Chronic Disease; Disease Progression; Disease Susceptibility; Humans; Nasal Pol

2021
Transcriptome Analysis Identifies Doublesex and Mab-3 Related Transcription Factor (DMRT3) in Nasal Polyp Epithelial Cells of Patients Suffering from Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease (AERD).
    Biomolecules, 2021, 07-23, Volume: 11, Issue:8

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; E

2021
Prognostic value of nasal cytology and clinical factors in nasal polyps development in patients at risk: can the beginning predict the end?
    International forum of allergy & rhinology, 2017, Volume: 7, Issue:9

    Topics: Adolescent; Adult; Aged; Aspirin; Asthma; Eosinophilia; Female; Humans; Male; Middle Aged; Nasal Muc

2017
Immunoglobulin G4 sinusitis in association with aspirin-exacerbated respiratory disease.
    American journal of rhinology & allergy, 2017, Sep-01, Volume: 31, Issue:5

    Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Immunoglobulin G; Male; Middle Aged; Nasal Polyps; Respira

2017
Outcomes after complete endoscopic sinus surgery and aspirin desensitization in aspirin-exacerbated respiratory disease.
    International forum of allergy & rhinology, 2018, Volume: 8, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo

2018
Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease.
    American journal of rhinology & allergy, 2018, Volume: 32, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-In

2018
Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study.
    Respiratory research, 2018, 06-27, Volume: 19, Issue:1

    Topics: Administration, Inhalation; Aspirin; Asthma; Case-Control Studies; Chronic Disease; Cross-Sectional

2018
Differences in urinary leukotriene E4 levels and distribution of eosinophils between chronic rhinosinusitis patients with aspirin-intolerant and-tolerant asthma.
    Nihon Jibiinkoka Gakkai kaiho, 2016, Volume: 119, Issue:12

    Topics: Aspirin; Asthma; Chronic Disease; Drug Tolerance; Eosinophils; Humans; Leukotriene E4; Rhinitis; Sin

2016
A retrospective analysis of esophageal eosinophilia in patients with aspirin-exacerbated respiratory disease.
    The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:4

    Topics: Aspirin; Asthma, Aspirin-Induced; Cyclooxygenase Inhibitors; Desensitization, Immunologic; Eosinophi

2019
A 1-Day, 90-Minute Aspirin Challenge and Desensitization Protocol in Aspirin-Exacerbated Respiratory Disease.
    The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:4

    Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cyclooxygenase Inhibitors; Desensitization, Immun

2019
Aspirin-Exacerbated Respiratory Disease.
    The New England journal of medicine, 2018, 12-06, Volume: 379, Issue:23

    Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Sinusitis

2018
Objective and subjective sinonasal and pulmonary outcomes in aspirin desensitization therapy: A prospective cohort study.
    Auris, nasus, larynx, 2019, Volume: 46, Issue:4

    Topics: Aged; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cohort Studies; Desensitization, Immunologi

2019
Aspirin-Exacerbated Respiratory Disease.
    The New England journal of medicine, 2018, 12-06, Volume: 379, Issue:23

    Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Sinusitis

2018
Aspirin-Exacerbated Respiratory Disease.
    The New England journal of medicine, 2018, 12-06, Volume: 379, Issue:23

    Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Sinusitis

2018
Aspirin Desensitization: Faster Protocols for Busy Patients.
    The journal of allergy and clinical immunology. In practice, 2019, Volume: 7, Issue:4

    Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Sinusitis

2019
[Nasal provocation with increased ASA dose: improved "non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated disease" (N‑ERD) detection rate in chronic rhinosinusitis patients].
    HNO, 2019, Volume: 67, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans;

2019
The bacteriology of chronic rhinosinusitis and the pre-eminence of Staphylococcus aureus in revision patients.
    International forum of allergy & rhinology, 2013, Volume: 3, Issue:8

    Topics: Adult; Aged; Aspirin; Asthma; Chronic Disease; Female; Humans; Male; Middle Aged; Nasal Polyps; Pseu

2013
Non-steroidal anti-inflammatory drug hypersensitivity in adults and the factors associated with asthma.
    Respiratory medicine, 2013, Volume: 107, Issue:7

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Drug Eruptions; Dr

2013
Aspirin sensitivity does not compromise quality-of-life outcomes in patients with Samter's triad.
    The Laryngoscope, 2014, Volume: 124, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease;

2014
Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.
    The Journal of allergy and clinical immunology, 2013, Volume: 132, Issue:4

    Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Cysteine; Cytokines; Eosinophils; Female; Humans; Interfer

2013
Short-term beneficial effect of aspirin in patient with chronic rhinosinusitis and tolerant to acetylsalicylic acid.
    Iranian journal of allergy, asthma, and immunology, 2013, Aug-28, Volume: 12, Issue:4

    Topics: Adult; Aspirin; Chronic Disease; Humans; Male; Rhinitis; Sinusitis

2013
Systemic prednisone administration selectively alters granulocyte subsets in nasal polyps from aspirin-exacerbated respiratory disease and chronic rhinosinusitis patients.
    International forum of allergy & rhinology, 2013, Volume: 3, Issue:11

    Topics: Adult; Aged; Aspirin; Chronic Disease; Ethmoid Sinus; Female; Flow Cytometry; Glucocorticoids; Granu

2013
Characterization and treatment of patients with chronic rhinosinusitis and nasal polyps.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2013, Volume: 111, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Asthma; Child; Drug Resistance; Eosinophils; Fe

2013
Concurrent coxibs and anti-platelet therapy unmasks aspirin-exacerbated respiratory disease.
    The European respiratory journal, 2013, Volume: 42, Issue:5

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cyclooxygenase 2 Inhibitors; Dyslipi

2013
Impact of vitamin D deficiency upon clinical presentation in nasal polyposis.
    International forum of allergy & rhinology, 2014, Volume: 4, Issue:3

    Topics: Age Factors; Allergens; Antigens, Fungal; Aspirin; Black or African American; Cholecalciferol; Chron

2014
Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?
    Current allergy and asthma reports, 2014, Volume: 14, Issue:6

    Topics: Aspirin; Chronic Disease; Desensitization, Immunologic; Drug Hypersensitivity; Drug Tolerance; Human

2014
Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2014, Volume: 151, Issue:4

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitizat

2014
Samter's triad with aural involvement: a novel approach to management.
    The Journal of laryngology and otology, 2014, Volume: 128, Issue:12

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Drug Hypersensitiv

2014
Phenotype of asthma related with high serum periostin levels.
    Allergology international : official journal of the Japanese Society of Allergology, 2015, Volume: 64, Issue:2

    Topics: Adult; Asian People; Aspirin; Asthma; Cell Adhesion Molecules; Cytokines; Drug Tolerance; Eosinophil

2015
Outcomes of complete vs targeted approaches to endoscopic sinus surgery.
    International forum of allergy & rhinology, 2015, Volume: 5, Issue:8

    Topics: Aspirin; Asthma; Chronic Disease; Endoscopy; Female; Humans; Male; Middle Aged; Nasal Polyps; Postop

2015
A conserved linkage group on chromosome 6, the 8.1 ancestral haplotype, is a predisposing factor of chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarians.
    Human immunology, 2015, Volume: 76, Issue:11

    Topics: Adolescent; Adult; Aged; Alleles; Aspirin; Case-Control Studies; Chromosomes, Human, Pair 6; Chronic

2015
Samter's Triad to Aspirin-Exacerbated Respiratory Disease: Historical Perspective and Current Clinical Practice.
    ORL-head and neck nursing : official journal of the Society of Otorhinolaryngology and Head-Neck Nurses, 2015,Autumn, Volume: 33, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-In

2015
Aspirin-Exacerbated Respiratory Disease--New Prime Suspects.
    The New England journal of medicine, 2016, Feb-04, Volume: 374, Issue:5

    Topics: Aspirin; Asthma; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Dinoprostone; Homeostasis; Humans; Nas

2016
Clinical Examination of Tissue Eosinophilia in Patients with Chronic Rhinosinusitis and Nasal Polyposis.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2016, Volume: 155, Issue:1

    Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Eosinophilia; Female; Humans; Male; Middle

2016
Clinical benefits of aspirin desensitization in patients with nonsteroidal anti-inflammatory drug exacerbated respiratory disease are not related to urinary eicosanoid release and are accompanied with decreased urine creatinine.
    Allergy and asthma proceedings, 2016, Volume: 37, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Creatine; Desensitization, Immunolo

2016
To anticoagulate? Controversy in the management of thrombotic complications of head & neck infections.
    International journal of pediatric otorhinolaryngology, 2016, Volume: 88

    Topics: Adolescent; Anticoagulants; Aspirin; Cavernous Sinus Thrombosis; Cerebral Angiography; Child; Child,

2016
Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria.
    Pediatric pulmonology, 2017, Volume: 52, Issue:5

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Female; Human

2017
Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2017, Volume: 274, Issue:3

    Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cross-Sectional Studies; Female; Humans; L

2017
Response to "The Role of Surgery in Management of Samter's Triad: A Systematic Review".
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2017, Volume: 156, Issue:2

    Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Humans; Nasal Polyps; Sinusitis

2017
Oral corticosteroid prescribing habits for rhinosinusitis: The American Rhinologic Society membership.
    American journal of rhinology & allergy, 2017, Jan-01, Volume: 31, Issue:1

    Topics: Administration, Oral; Adrenal Cortex Hormones; Aspirin; Chronic Disease; Evidence-Based Medicine; Hu

2017
Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2008, Volume: 100, Issue:5

    Topics: Administration, Oral; Adult; Age Factors; Aspirin; Asthma; Drug Hypersensitivity; Female; Forced Exp

2008
[From wheezing to anaphylactic shock: allergology for your practice].
    MMW Fortschritte der Medizin, 2008, Mar-27, Volume: 150, Issue:13

    Topics: Adult; Allergy and Immunology; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2008
[Nonallergic diseases of the upper and lower airways].
    Therapeutische Umschau. Revue therapeutique, 2008, Volume: 65, Issue:3

    Topics: Aspirin; Asthma; Bronchitis; Diagnosis, Differential; Drug Hypersensitivity; Eosinophilia; Humans; I

2008
Correlation between the prostaglandin D(2)/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma.
    Allergology international : official journal of the Japanese Society of Allergology, 2008, Volume: 57, Issue:4

    Topics: Adult; Aged; Aspirin; Asthma; Cell Extracts; Chronic Disease; Dinoprostone; Drug Hypersensitivity; E

2008
Otologic manifestations in Samter's syndrome.
    ORL; journal for oto-rhino-laryngology and its related specialties, 2009, Volume: 71, Issue:1

    Topics: Aspirin; Asthma; Chronic Disease; Cohort Studies; Drug Hypersensitivity; Ear Diseases; Ear, Middle;

2009
Proteomics blood testing to distinguish chronic rhinosinusitis subtypes.
    The Laryngoscope, 2008, Volume: 118, Issue:12

    Topics: Aspirin; Asthma; Biomarkers; Chronic Disease; Diagnosis, Differential; Drug Hypersensitivity; Fungi;

2008
Combined effect of IL-10 and TGF-beta1 promoter polymorphisms as a risk factor for aspirin-intolerant asthma and rhinosinusitis.
    Allergy, 2009, Volume: 64, Issue:8

    Topics: Adult; Alleles; Aspirin; Asthma; Drug Hypersensitivity; Epistasis, Genetic; Female; Gene Frequency;

2009
Chemokine CC-ligand 5 production and eosinophil activation into the upper airways of aspirin-sensitive patients.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2009, Volume: 39, Issue:4

    Topics: Administration, Intranasal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chemoki

2009
[Chronic rhinosinusitis and aspirin intolerance].
    MMW Fortschritte der Medizin, 2009, Jan-29, Volume: 151, Issue:5

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Spasm; Desensitization, I

2009
Unmet needs in severe chronic upper airway disease (SCUAD).
    The Journal of allergy and clinical immunology, 2009, Volume: 124, Issue:3

    Topics: Allergens; Aspirin; Child; Chronic Disease; Drug Hypersensitivity; Humans; Nasal Polyps; Prevalence;

2009
Aspirin sensitivity and the nose.
    British journal of hospital medicine (London, England : 2005), 2010, Volume: 71, Issue:8

    Topics: Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Humans; Nasal Polyps; Respiration Disorders

2010
[The treatment of polypous suppurative rhinosinusitis in the patients presenting with the severe and moderate aspirin triad].
    Vestnik otorinolaringologii, 2011, Issue:4

    Topics: Aspirin; Asthma; Humans; Nasal Polyps; Rhinitis; Sinusitis; Suppuration

2011
Low SPINK5 expression in chronic rhinosinusitis.
    The Laryngoscope, 2012, Volume: 122, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity;

2012
Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4.
    Polskie Archiwum Medycyny Wewnetrznej, 2012, Volume: 122, Issue:9

    Topics: Adult; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Female; Humans; Leukotriene E4; Male

2012
[Expressions of EOS and COX-2 in nasal polyps in patients with aspirin triad syndrome and its significance].
    Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery, 2012, Volume: 26, Issue:11

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cyclooxygenase 2; Endoscopy; Eosino

2012
Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization.
    Seminars in respiratory and critical care medicine, 2012, Volume: 33, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo

2012
A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2002, Volume: 32, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Case-Control Studies; Drug Hypersensitivit

2002
Leukotriene receptors and aspirin sensitivity.
    The New England journal of medicine, 2002, Nov-07, Volume: 347, Issue:19

    Topics: Aspirin; Asthma; Desensitization, Immunologic; Down-Regulation; Drug Hypersensitivity; Humans; Membr

2002
Can NSAIDs intolerance disappear? A study of three cases.
    Allergy, 2003, Volume: 58, Issue:7

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Drug Hypersensitivity; Forced Expir

2003
[THERAPEUTIC USE OF THE COMBINATION OF CHYMOTRYPSIN WITH ACETYLSALICYLIC ACID IN PEDIATRICS].
    Gazette medicale de France, 1963, Sep-10, Volume: 70

    Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Aspirin; Bronchitis; Child; Chymotrypsin; Fever;

1963
COMPARATIVE EFFECTIVENESS OF THREE ORAL MEDICATIONS IN SINUSTIS AND RHINITIS; A DOUBLE-BLIND STUDY.
    Medical times, 1964, Volume: 92

    Topics: Anti-Allergic Agents; Aspirin; Biomedical Research; Codeine; Double-Blind Method; Headache; Histamin

1964
[VALUE OF CHYMALGYL IN OTORHINOLARYNGOLOGICAL PATHOLOGY. APROPOS OF 20 CASES].
    Gazette medicale de France, 1965, Jan-10, Volume: 72

    Topics: Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antipyretics; Aspirin; Drug Therapy;

1965
Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis.
    The Journal of allergy and clinical immunology, 2004, Volume: 113, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Case-Contr

2004
Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis.
    The Journal of allergy and clinical immunology, 2004, Volume: 114, Issue:4

    Topics: Adult; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Enterotoxins; Female; Humans; Immuno

2004
Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis.
    The Journal of allergy and clinical immunology, 2005, Volume: 115, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Epithelial Cells; Fe

2005
Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2005, Volume: 94, Issue:6

    Topics: Adult; Aspirin; Asthma; Case-Control Studies; Chronic Disease; Cohort Studies; Drug Hypersensitivity

2005
Characterisation of patients with frequent exacerbation of asthma.
    Respiratory medicine, 2006, Volume: 100, Issue:2

    Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As

2006
Characterisation of patients with frequent exacerbation of asthma.
    Respiratory medicine, 2006, Volume: 100, Issue:2

    Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As

2006
Characterisation of patients with frequent exacerbation of asthma.
    Respiratory medicine, 2006, Volume: 100, Issue:2

    Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As

2006
Characterisation of patients with frequent exacerbation of asthma.
    Respiratory medicine, 2006, Volume: 100, Issue:2

    Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As

2006
Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest).
    Allergy, 2005, Volume: 60, Issue:9

    Topics: Adult; Aged; Aspirin; Asthma; Drug Hypersensitivity; Female; Humans; Hydroxyeicosatetraenoic Acids;

2005
The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2005, Volume: 95, Issue:4

    Topics: Administration, Oral; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Anti-Inflammatory Agents, N

2005
Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells.
    The Journal of allergy and clinical immunology, 2006, Volume: 117, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Chronic Disease; Drug Hyperse

2006
Does it make sense to "desens"? Aspirin desensitization in the treatment of chronic rhinosinusitis.
    Current allergy and asthma reports, 2006, Volume: 6, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease; Desensitization, Immunolo

2006
Association between a TGFbeta1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients.
    Respiratory medicine, 2007, Volume: 101, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Drug Hypersensitivity; Female; Gene

2007
Different eicosanoid profile of the hypersensitivity reactions triggered by aspirin and celecoxib in a patient with sinusitis, asthma, and urticaria.
    The Journal of allergy and clinical immunology, 2006, Volume: 118, Issue:4

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celecoxib; Drug Hypersensitivity; E

2006
Allergy and sinus disease.
    The Medical journal of Australia, 2006, Nov-20, Volume: 185, Issue:10

    Topics: Anti-Allergic Agents; Aspirin; Drug Hypersensitivity; Humans; Nasal Polyps; Respiratory Hypersensiti

2006
Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2007, Volume: 98, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Desensitization, Immunologic; Drug Hyperse

2007
Impact of aspirin intolerance on outcomes of sinus surgery.
    The Laryngoscope, 2007, Volume: 117, Issue:5

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chi-Square Distribution; Chronic Dise

2007
The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery.
    Ear, nose, & throat journal, 2007, Volume: 86, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Asthma; Child; Child, Preschool; Chronic Diseas

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict?
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2007, Volume: 137, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma

2007
BSACI guidelines for the management of rhinosinusitis and nasal polyposis.
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2008, Volume: 38, Issue:2

    Topics: Aspirin; Child; Churg-Strauss Syndrome; Female; Humans; Male; Nasal Polyps; Rhinitis; Sinusitis

2008
Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma.
    The Laryngoscope, 2008, Volume: 118, Issue:5

    Topics: Adipokines; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Carrier Proteins; Chrom

2008
[ASA-intolerance (Samter's syndrome): an important differential diagnosis for chronic airway diseases].
    MMW Fortschritte der Medizin, 2008, Feb-28, Volume: 150, Issue:9

    Topics: Aspirin; Asthma; Chronic Disease; Diagnosis, Differential; Drug Hypersensitivity; Humans; Nasal Poly

2008
[Inhalation provocation test with lysine acetylsalicylic acid (Aspisol)--a useful method for the diagnosis of analgesic asthma].
    Zeitschrift fur Erkrankungen der Atmungsorgane, 1984, Volume: 163, Issue:1

    Topics: Airway Resistance; Analgesics; Aspirin; Asthma; Bronchi; Bronchial Provocation Tests; Drug Hypersens

1984
Aspirin-sensitive asthma and rhinosinusitis: current concepts and recent advances.
    Ear, nose, & throat journal, 1984, Volume: 63, Issue:2

    Topics: Adult; Aspirin; Asthma; Desensitization, Immunologic; Drug Tolerance; Humans; Rhinitis; Sinusitis

1984
[Rhinosinusitis polyposa and intolerance to analgesics (aspirin intolerance)].
    Laryngologie, Rhinologie, Otologie, 1983, Volume: 62, Issue:3

    Topics: Adult; Aged; Analgesics; Aspirin; Bronchial Provocation Tests; Drug Hypersensitivity; Drug Tolerance

1983
Aspirin-sensitive rhinosinusitis: the clinical syndrome and effects of aspirin administration.
    The Journal of allergy and clinical immunology, 1983, Volume: 71, Issue:6

    Topics: Adult; Aged; Aspirin; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Indometha

1983
Aspirin-sensitive rhinosinusitis/asthma: spectrum of adverse reactions to aspirin.
    The Journal of allergy and clinical immunology, 1983, Volume: 71, Issue:6

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aspirin; Asthma; Drug Hypersensitivity; Forced Exp

1983
Aspirin-induced asthma in children.
    Annals of allergy, 1982, Volume: 48, Issue:1

    Topics: Acetylation; Adolescent; Anti-Inflammatory Agents; Aspirin; Asthma; Child; Complement System Protein

1982
Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis.
    The Journal of allergy and clinical immunology, 1995, Volume: 96, Issue:4

    Topics: Adolescent; Adult; Aspirin; Cell Movement; Cytokines; Drug Hypersensitivity; Eosinophilia; Eosinophi

1995
Histamine metabolism in nasal polyps.
    The Annals of otology, rhinology, and laryngology, 1993, Volume: 102, Issue:2

    Topics: Amine Oxidase (Copper-Containing); Aspirin; Asthma; Bronchial Provocation Tests; Histamine; Histamin

1993
Nasal secretions in response to acetylsalicylic acid.
    The Journal of allergy and clinical immunology, 1993, Volume: 91, Issue:2

    Topics: Adult; Aged; Aspirin; Asthma; Drug Hypersensitivity; Female; Humans; Inflammation; Male; Middle Aged

1993
Orbital complications of sinusitis in the aspirin triad syndrome.
    The Laryngoscope, 1996, Volume: 106, Issue:9 Pt 1

    Topics: Adolescent; Adult; Aged; Aspirin; Asthma; Chronic Disease; Female; Humans; Male; Middle Aged; Orbita

1996
Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes.
    The Journal of allergy and clinical immunology, 1996, Volume: 98, Issue:4

    Topics: Adult; Aspirin; Asthma; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Outcome Assessm

1996
Ketorlac-induced status asthmaticus after endoscopic sinus surgery in a patient with Samter's triad.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1997, Volume: 117, Issue:6

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Drug Hypersensitivity; Endoscopy; F

1997
Medical management of sinusitis.
    The American journal of the medical sciences, 1998, Volume: 316, Issue:1

    Topics: Adrenal Cortex Hormones; Aspirin; Drainage; Humans; Hypersensitivity; Nasal Decongestants; Nasal Sep

1998
[A case of aspirin triad].
    Vestnik otorinolaringologii, 1999, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Drug Hypersensitivity; Follow-Up

1999
Effects of sinus surgery on asthma in aspirin triad patients.
    Acta oto-laryngologica, 1999, Volume: 119, Issue:5

    Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Airway Resistance; Aspirin; Asthma; Chro

1999
Antileukotriene therapy for the relief of sinus symptoms in aspirin triad disease.
    Ear, nose, & throat journal, 1999, Volume: 78, Issue:8

    Topics: Adult; Aged; Aspirin; Asthma; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Indoles; Leu

1999
[Significance of eosinophilic granulocytes in relation to allergy and aspirin intolerance in patients with sinusitis polyposa].
    Laryngo- rhino- otologie, 1999, Volume: 78, Issue:8

    Topics: Adult; Aged; Aspirin; Drug Hypersensitivity; Eosinophilia; Eosinophils; Female; Humans; Male; Middle

1999
Outcome analysis of endoscopic sinus surgery for chronic sinusitis in patients having Samter's triad.
    The Journal of otolaryngology, 2000, Volume: 29, Issue:1

    Topics: Adult; Age of Onset; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Chronic Disease

2000
[Family study of patients with aspirin intolerance and rhinosinusitis].
    HNO, 2000, Volume: 48, Issue:9

    Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provocation T

2000
Drug Points: tachycardia associated with moxifloxacin.
    BMJ (Clinical research ed.), 2001, Jan-06, Volume: 322, Issue:7277

    Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Aza Compounds; Bronchitis;

2001
Individual monitoring of aspirin desensitization.
    Archives of otolaryngology--head & neck surgery, 2001, Volume: 127, Issue:3

    Topics: Adult; Aged; Aspirin; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Male; Mid

2001
[Cellular antigen stimulation test (CAST). A new possibility in diagnosis of aspirin-sensitivity rhinosinusitis?].
    HNO, 2001, Volume: 49, Issue:3

    Topics: Aspirin; Drug Hypersensitivity; Enzyme-Linked Immunosorbent Assay; Humans; Leukocytes; Leukotriene C

2001
Aspirin desensitization for chronic hyperplastic sinusitis, nasal polyposis, and asthma triad.
    Archives of otolaryngology--head & neck surgery, 2001, Volume: 127, Issue:10

    Topics: Adult; Aged; Aspirin; Asthma; Chronic Disease; Desensitization, Immunologic; Drug Hypersensitivity;

2001
Decreased apoptosis and distinct profile of infiltrating cells in the nasal polyps of patients with aspirin hypersensitivity.
    Allergy, 2002, Volume: 57, Issue:6

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Antigens, Differentiation, Myelo

2002
[Rhinosinusitis polyposa as the only symptom of aspirin intolerance -- a rhinorheomanometric diagnosis (author's transl)].
    Laryngologie, Rhinologie, Otologie, 1977, Volume: 56, Issue:2

    Topics: Aspirin; Drug Hypersensitivity; Female; Humans; Manometry; Maxillary Sinus; Middle Aged; Nasal Polyp

1977
Hypersensitivity to nonsteroidal antiinflammatory drugs: indications and methods for oral challenges.
    The Journal of allergy and clinical immunology, 1979, Volume: 64, Issue:6 pt 2

    Topics: Anti-Inflammatory Agents; Aspirin; Asthma; Bronchial Provocation Tests; Drug Hypersensitivity; Human

1979
Aspirin and concomitant idiosyncrasies in adult asthmatic patients.
    The Journal of allergy and clinical immunology, 1979, Volume: 64, Issue:6 Pt 1

    Topics: Acetaminophen; Administration, Oral; Adolescent; Adult; Aged; Aspirin; Asthma; Azo Compounds; Drug H

1979
Aspirin-improved ASA triad.
    Hospital practice, 1978, Volume: 13, Issue:8

    Topics: Aspirin; Asthma; Female; Humans; Middle Aged; Nasal Polyps; Sinusitis

1978
Aspirin intolerance in asthmatic patients: case histories.
    Annals of allergy, 1977, Volume: 38, Issue:4

    Topics: Adult; Aspirin; Asthma; Female; Humans; Rhinitis; Sinusitis

1977
Provoking factors in bronchial asthma.
    Archives of internal medicine, 1975, Volume: 135, Issue:6

    Topics: Adolescent; Adult; Aged; Aspirin; Asthma; Bronchitis; Child; Child, Preschool; Drug Hypersensitivity

1975
Tryptase and histamine release during aspirin-induced respiratory reactions.
    The Journal of allergy and clinical immunology, 1991, Volume: 88, Issue:6

    Topics: Administration, Oral; Adult; Aspirin; Asthma; Forced Expiratory Volume; Histamine; Histamine Release

1991
Surgery for sinusitis and aspirin triad.
    The Laryngoscope, 1990, Volume: 100, Issue:10 Pt 1

    Topics: Adolescent; Adult; Aspirin; Asthma; Chronic Disease; Drug Hypersensitivity; Female; Follow-Up Studie

1990
Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma.
    The Journal of allergy and clinical immunology, 1990, Volume: 85, Issue:1 Pt 1

    Topics: Adrenal Cortex Hormones; Adult; Aspirin; Asthma; Combined Modality Therapy; Desensitization, Immunol

1990
Immunohistological characteristics of nasal polyps. A comparison with healthy mucosa and chronic sinusitis.
    Rhinology. Supplement, 1989, Volume: 8

    Topics: Adolescent; Adult; Aged; Antigen-Antibody Complex; Aspirin; Asthma; Complement System Proteins; Drug

1989
Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy.
    The Journal of allergy and clinical immunology, 1988, Volume: 82, Issue:6

    Topics: Adolescent; Adult; Aged; Allergens; Animals; Antigens, Dermatophagoides; Aspirin; Asthma; Child; Chi

1988
Histopathology and immunofluorescent immunoglobulins in asthmatics with aspirin idiosyncrasy.
    Archives of otolaryngology--head & neck surgery, 1987, Volume: 113, Issue:4

    Topics: Adult; Aspirin; Asthma; Drug Hypersensitivity; Female; Fluorescent Antibody Technique; Humans; Immun

1987
Prevalence of aspirin intolerance in asthmatics treated in a hospital.
    Respiration; international review of thoracic diseases, 1986, Volume: 50, Issue:3

    Topics: Aspirin; Asthma; Bronchial Provocation Tests; Drug Hypersensitivity; Female; Hospitalization; Humans

1986
Nasal polypectomy and sinus surgery in patients with asthma and aspirin idiosyncrasy.
    The Laryngoscope, 1986, Volume: 96, Issue:4

    Topics: Adolescent; Adult; Aspirin; Asthma; Bronchial Provocation Tests; Chronic Disease; Drug Hypersensitiv

1986
[Diagnostic and therapeutic methods in the asthmatic triad].
    Terapevticheskii arkhiv, 1985, Volume: 57, Issue:11

    Topics: Adolescent; Adult; Aspirin; Asthma; Bronchial Provocation Tests; Child; Desensitization, Immunologic

1985
Aspirin disease and adverse effects.
    The Nebraska state medical journal, 1971, Volume: 56, Issue:11

    Topics: Adult; Aspirin; Asthma; Blood Platelet Disorders; Female; Gastrointestinal Hemorrhage; Humans; Male;

1971
Allergic disorders of the nose and paranasal sinuses.
    Otolaryngologic clinics of North America, 1974, Volume: 7, Issue:3

    Topics: Aspirin; Drug Hypersensitivity; Dust; Humans; Nasal Polyps; Pollen; Rhinitis, Allergic, Seasonal; Si

1974
[A new anti-inflammatory agent: calcium bucloxate in pediatrics].
    Arzneimittel-Forschung, 1974, Volume: 24, Issue:9A SUPPL

    Topics: Adolescent; Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Bronchopneumonia;

1974
Aspirin intolerance. II. A prospective study in an atopic and normal population.
    The Journal of allergy and clinical immunology, 1974, Volume: 53, Issue:4

    Topics: Allergens; Angioedema; Aspirin; Asthma; Bronchial Spasm; Drug Hypersensitivity; Female; Humans; Male

1974
Aspirin intolerance in asthma. Detection by oral challenge.
    The Journal of allergy and clinical immunology, 1972, Volume: 50, Issue:4

    Topics: Adult; Aspirin; Asthma; Drug Hypersensitivity; Female; Glucocorticoids; Humans; Male; Polyps; Respir

1972